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Leukemias are routinely sub-typed for risk/outcome prediction and therapy choice using acquired 34 
mutations and chromosomal rearrangements. Down syndrome acute lymphoblastic leukemia (DS-35 
ALL) is characterized by high frequency of CRLF2-rearrangements, JAK2-mutations, or RAS-pathway 36 
mutations. Intriguingly, JAK2 and RAS-mutations are mutually exclusive in leukemic sub-clones, 37 
causing dichotomy in therapeutic target choices.  We prove in a cell model that elevated CRLF2 in 38 
combination with constitutionally active JAK2 is sufficient to activate wtRAS. On primary clinical DS-39 
ALL samples, we show that wtRAS-activation is an obligatory consequence of 40 
mutated/hyperphosphorylated JAK2. We further prove that CRLF2-ligand TSLP boosts the direct 41 
binding of active PTPN11 to wtRAS, providing the molecular mechanism for the wtRAS activation. 42 
Pre-inhibition of RAS or PTPN11, but not of PI3K or JAK-signaling, prevented TSLP-induced RAS-GTP 43 
boost. Cytotoxicity assays on primary clinical DS-ALL samples demonstrated that, regardless of 44 
mutation status, high-risk leukemic cells could only be killed using RAS-inhibitor or PTPN11-inhibitor, 45 
but not PI3K/JAK-inhibitors, suggesting a unified treatment target for up to 80% of DS-ALL. 46 
Importantly, protein activities-based principal-component-analysis multivariate clusters analyzed for 47 
independent outcome prediction using Cox proportional-hazards model showed that protein-activity 48 
(but not mutation-status) was independently predictive of outcome, demanding a paradigm-shift in 49 
patient-stratification strategy for precision therapy in high-risk ALL.  50 




Acute lymphoblastic leukemia (ALL) is the most common malignancy and cancer-related cause of 52 
death at pediatric age(1, 2). Despite a considerable success rate of standard chemotherapy 53 
treatments, as many as 10-15% of children with ALL have recurrent disease (relapses)(3, 4). Patients 54 
with high-risk (HR) forms of ALL show increased incidence of relapses, poorer prognosis and lower 55 
overall 5-year survival rates following relapse(5). Recently, significant progress has been achieved in 56 
understanding the mechanistic consequences of individual pathways affected in HR-ALL, and the 57 
resulting selection of therapeutic targets leading to clinical trials using pathway-specific drugs, such 58 
as JAK/STAT inhibitors (6). Recent detailed studies of the evolution of acquired genomic changes in 59 
ALL identified certain sub-types as being particularly HR forms (7, 8). Among these are hypodiploid 60 
ALL(9), Philadelphia chromosome-like (Ph-like) type (defined as a type of ALL with the genomic 61 
profile similar to that of the Ph+ ALL)(8, 10, 11), ALL with an intrachromosomal amplification of 62 
chromosome 21 (iAMP21)(12, 13), and ALL in children with Down syndrome (DS-ALL)(14, 15).  63 
The acquired mutations landscape does not find a unifying profile that distinguishes HR childhood 64 
ALL from non-HR childhood ALL, suggesting the need for individualized therapy approach(16) 65 
preceded by individual patient sub-type assignment based on the mutational profile analysis. While 66 
Ph-like ALL has a high incidence (60%) of genomic rearrangements leading to an increased 67 
expression of the receptor to the cytokine TSLP, CRLF2(17), and more than half of these have 68 
mutations in JAK and IL7R pathway - including constitutionally activating JAK2 mutations(11, 18, 19), 69 
less than 10% of Ph-like ALL also acquire RAS/MAPK pathway mutations.  DS-ALL is distinguished by 70 
the similarly high presence of both CRLF2-rearrangements (60%) (with JAK2 mutations at 32%), with 71 
a higher proportion of RAS-MAPK pathway mutations (36%)(20, 21). Intriguingly, a near complete 72 
mutual exclusion between JAK2 and RAS mutations in diagnosis samples, or individual sub-clones of 73 
relapse samples of DS-ALL is repeatedly observable(20, 21). 74 
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We hypothesized that the reason for this mutual exclusion is that increased CRLF2-levels in 75 
combination with JAK2 activation could be sufficient to activate wild-type (wt) RAS protein in the 76 
absence of RAS mutations. 77 
  78 
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Materials and Methods 79 
 80 
Cell culture and cell viability 81 
Ba/F3 (Cat.#RCB0805), a murine IL-3 dependent pro-B cell line, was obtained from RIKEN 82 
BioResource Center (Tsukuba, Japan) and MUTZ-5 (Cat.#ACC490), a human B cell precursor leukemia 83 
cell line established at relapse, was obtained from the Leibniz Institute DSMZ (Braunschweig, 84 
Germany); authenticated via multiplex PCR of minisatellite markers. Mycoplasma-free cells were 85 
routinely passaged (passage range for shown experiments: 15-35) according to the respective cell 86 
bank recommendations. Handling of primary patient samples is described in detail in Supplementary 87 
material.  88 
Cell count and cell viability (percentage of acridine orange-positive cells not stained by 4',6-89 
diamidino-2-phenylindole (DAPI) were determined in an NC-250 automated cell-analyzer 90 
(ChemoMetec, Allerod, DK).  91 
 92 
Patient samples 93 
Surplus clinical or archived clinical material for peripheral blood/bone marrow samples of DS-ALL 94 
and non-DS ALL patients was collected by the tissue bank of the Italian Association for Paediatric 95 
Haematology-Oncology (AIEOP). In accordance with the Declaration of Helsinki, informed written 96 
consent was obtained by the tissue bank for all subjects. Samples were processed and stored in the 97 
tissue bank at The Blizard Institute, which is licensed for tissue storage and monitored by UK-Human 98 
Tissue Authority. Detailed clinical description of studied DS-ALLs and Non-DS B-ALLs is available in 99 
Supplementary-Tab.S1. Detailed cytogenetics was available in 12 cases.  100 
MS2003/2010 cohort(22, 23) RNA-seq data was submitted to the European Genome-phenome 101 
Archive (Accession# EGAS00001001858). 102 
 103 
 104 
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RAS activity assays 105 
Cells were left uninduced or induced with human TSLP at 37 °C. Whenever indicated, DMSO or 106 
inhibitors were added for 3 hrs before TSLP-induction. Cells were lysed on ice at 1000 cells/µL lysis 107 
buffer according to the manufacturer’s protocol of the active RAS detection kit (Cat.#8821; Cell 108 
Signaling Technology). Total protein concentrations of samples were measured using a BCA protein-109 
assay kit (Cat.#23225; ThermoFisher Scientific). 50 µg total protein was loaded per column of the 110 
active RAS detection kit for Western blot (WB). In the RAS activation assay kit for ELISA (Cat.#17-497; 111 
EMD Millipore), 12 µg total protein was used at 100 ng/µL and the RAS-GTP pull-down was 112 
measured using a Synergy H1 plate reader (BioTek, Winooski, US) in luminescent mode. 113 
 114 
 115 
For methods on proximity ligation assay (PLA), principal-component-analysis (PCA), statistical 116 
analysis, as well as lists of antibodies/chemicals, and standard protocols for the sequencing, SDS-117 
PAGE/WB, phospho-protein antibody-microarray, and transduction please see “Supplementary 118 
Methods”. 119 
  120 





CRLF2 and JAK2mut co-expression is sufficient to activate RAS in Ba/F3 cells 123 
We hypothesized that increased CRLF2-level in combination with a mutation in JAK2 pathway genes 124 
could be sufficient to activate wtRAS protein in the absence of RAS mutations, as a mechanism to 125 
explain the mutual exclusion of JAK2 and RAS/MAPK mutations in DS-ALL.   The level of RAS activity 126 
is generally assessed using a pull-down assay whereby the (activated) RAS-GTP is captured by virtue 127 
of its high affinity to RAS-binding-domain (RBD) of RAF proteins.  In order to observe the effects of 128 
elevated CRLF2 signaling on the activation of RAS, we stably integrated a human CRLF2 129 
overexpression construct(24) into the mouse pre-B-cell line Ba/F3. This alteration did not increase 130 
the level of pulled-down RAS-GTP (Fig.1A) and neither did the stable overexpression of 131 
hJAK2R683G(24), the most prevalent specific activating JAK2 mutation in DS-ALL and Ph-like-ALL. 132 
However, when both of these alterations were combined, eight fold higher RAS-GTP level was 133 
measured, in the absence of cytokines (Fig.1B, post-hoc Bonferroni p-values are listed in 134 
Supplementary-Tab.S2). An independent set of Ba/F3 lines, in which CRLF2 was transduced first, 135 
confirms that this increased RAS-activity is not due to variations in CRLF2 overexpression levels 136 
within the lines (Supplementary-Fig.S1F). Growth of Ba/F3 cells depends on IL-3 (Supplementary-137 
Fig.S1A), which induces wtJAK2 phosphorylation(25), and interestingly we found that it also activates 138 
RAS (Supplementary-Fig.S1B). The cells with combined CRLF2 and JAK2R683G overexpression were the 139 
only ones in this series that grew in a cytokine-independent manner (Supplementary-Fig.S1E), as also 140 
previously observed(24). This proves that increased CRLF2-expression together with activated JAK2 141 
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TSLP-inducible RAS activity in absence of RAS mutations is a feature of human CRLF2 rearranged B-147 
ALL 148 
In order to prove the observations from Fig.1 in human ALL cells, we selected a B-ALL cell line that 149 
harbors identical changes as our double-transfected model line in Fig.1. The B cell precursor 150 
leukemia cell line MUTZ-5 from a relapsed Philadelphia-like B-ALL patient features a CRLF2-151 
translocation leading to wt CRLF2 overexpression, as well as the JAK2R683G mutation, and the absence 152 
of mutations in any RAS-MAPK pathway genes(26). The absence of RAS mutations in the MUTZ-5 153 
cells grown in our cultures was confirmed by performing standard Sanger DNA-sequencing of PCR-154 
amplicons from genomic DNA, encompassing all exons of KRAS, NRAS and HRAS genes 155 
(Supplementary-Tab.S3). We detected the presence of activated RAS in these cells by RAF-RBD pull-156 
down of RAS-GTP (Fig.2A), which was tripled upon a 10 min induction with the CRLF2-ligand TSLP. 157 
Similar results were reproduced using an ELISA-based RAS-pull-down (Fig.2C). Both immediate 158 
upstream (PTPN11) and immediate downstream (MEK1/2, bRAF) components of the RAS/MAPK 159 
pathway were also induced by TSLP induction (Fig.2A, Fig.2B). The direct binding of activated RAS 160 
and bRAF proteins expressed in these cells (Supplementary-Fig.S2A) was further validated via PLA 161 
(Supplementary-Fig.S2B), as was RAS and phospho-PTPN11 interaction in the Ba/F3 model 162 
(Supplementary-Fig.S3B).  Both KRAS and NRAS, but not HRAS, isoforms showed increased activity 163 
after TSLP-induction (Fig.2C). Interestingly, the genes for the same two isoforms (KRAS and NRAS), 164 
but not HRAS, acquire mutations in B-ALL(12, 20). Therefore, we conclude that the RAS isoform 165 
activity pattern of TSLP-inducibility in wtRAS leukemia cells matches the isoforms that acquire 166 
mutations in RAS-mutated leukemia cases. Furthermore, we traced TSLP-signaling throughout 167 
cellular pathways in 68 individual protein-phosphorylation sites via an antibody-based phospho-168 
array (Supplementary-Fig.S4C). The phospho-array confirmed the increased phosphorylation 169 
observed for denatured proteins in WB for STAT5A, ERK1/2, MEK1, and JAK2 on their respective 170 
native epitopes (Supplementary-Fig.S4C) while the most statistically significant results demonstrate 171 
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additional TSLP-effects by increasing activating phosphorylations (AKT2, CDKN1A, ELK1) but also by 172 
downregulating pathway-inhibiting phosphorylations (cRAF(Ser296), GAB2, MYC, PTPN6) (Fig.2E). 173 
 174 
RAS inhibitor can significantly block the growth of human B-ALL Ph-like wtRAS cells 175 
We next examined to what extent the direct RAS activation in wtRAS leukemic cells affects the cell 176 
growth and viability. We tracked the cell count and cell viability of MUTZ-5 cells after treatment with 177 
pan-wtRAS-inhibitor and in comparison to treatments with other compounds that have been 178 
previously reported to induce dose-dependent cytotoxicity in MUTZ-5(27), some of which are 179 
currently in clinical trials for Ph-like ALL(6).  After 4 days treatment with pan-wtRAS inhibitor the 180 
growth and viability of MUTZ-5 cells were significantly reduced (Fig.3A,B), and this was not affected 181 
by the presence of TSLP. In comparison, the dual PI3K/mTOR inhibitor also significantly reduced the 182 
growth and viability of MUTZ-5 cells, but this inhibitory effect could be partially counteracted by the 183 
TSLP-induction (Fig.3A). Both of these compounds, at the concentrations used (tested to achieve 184 
high efficacy on the respective main pathway target in WB, Fig.3C), showed a much stronger 185 
inhibitory effect on cell growth than the JAK inhibitor (Fig.3A), despite the observation that this 186 
concentration of JAK-inhibitor, which blocks almost all STAT5-signaling (Fig.3C, Fig.3E), showed the 187 
strongest inhibition of TSLP-induced phosphorylation of MEK1/2, PTPN11, ERK1/2 and rpS6 (Fig.3C, 188 
right-hand side blots). However, neither the JAK inhibitor, nor the PI3K/mTOR inhibitor could block 189 
the wtRAS activation by TSLP as shown in WB (Fig.3C, left-hand side blots) and ELISA (Fig.3D). For the 190 
JAK2 inhibitor this might be explained by its failure to reduce the direct interaction between RAS and 191 
PTPN11 in PLA (Supplementary-Fig.S2E). In contrast, the pan-wtRAS-inhibitor significantly blocked 192 
the TSLP-induced RAS-activity (Fig.3C, left-hand side blot) and ELISA (Fig.3D). Moreover, the pre-193 
inhibition of RAS-direct interacting proteins (RAF and PTPN11) also reduced TSLP-induced wtRAS 194 
boost in human Ph-ALL cells (Fig.3C). Combined, our data suggest that TSLP-activation of RAS in the 195 
absence of RAS mutations drives B-ALL cell growth, and represents an independent drug target, in 196 
addition to the PI3K/mTOR and JAK/STAT pathway targets. 197 





DS-ALL patients differ in the level of activity and inducibility of RAS, independently of RAS 200 
mutations 201 
The MUTZ-5 ALL cells used in the analysis so far share the increased CRLF2 expression and mutated 202 
JAK2 with approximately a third of DS-ALL patients(20), which also have no mutations in RAS genes. 203 
We therefore analyzed primary cells from presentation samples (at primary diagnosis) of DS-ALL in 204 
RAS pull-down WB and ELISA assay measurements (+/- TSLP stimulation). The analyses were 205 
performed blinded to the mutation profile of the patient material and distinct DS-ALL patient 206 
profiles for RAS-activity and TSLP-inducibility of RAS were observed in WB (Fig.4A) and confirmed by 207 
ELISA (Fig.4B). As we see examples of RAS-mutated, wtRAS, or JAK2-mutated DS-ALL in each of the 208 
profile types (Fig.4C), with exception of low-RAS and non-inducible type, we can conclude that 209 
activity levels and TSLP-inducibility of RAS cannot be predicted on the basis of DNA-sequencing 210 
(acquired mutations) patterns. 211 
The most important conclusion of this analysis is that RAS is active/inducible in 14/20 (70%) of 212 
primary DS-ALL samples analyzed, 8 of which had no RAS mutations, but 75% of those had either 213 
mutated or hyperphosphorylated JAK2 (Fig.4C). This means that either the RAS mutation, or the 214 
combination of high CRLF2 and hyperphosphorylated JAK2 (including mutated JAK2) can explain the 215 
mechanism for high RAS activity in 12/14 (86%) of DS-ALL with high RAS activity. Importantly, not a 216 
single wtRAS case with either mutated or hyperphosphorylated JAK2 was seen that lacked activated 217 
RAS protein (Fig.4C), suggesting that RAS activation is an obligatory consequence in wtRAS DS-ALL 218 
cases with mutated or hyperphosphorylated JAK2. 219 
 220 
RAS activity and its TSLP inducibility correlate with outcome in DS-ALL patients 221 
Data from primary cells analysis from n=20 presentation samples of DS-ALL for the RAS/MAPK, 222 
PI3K/mTOR, and JAK/STAT pathway activity profiles using WB (Supplementary-Fig.S5A, 223 
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Supplementary-Fig.S5B), as well as ELISA for activated RAS-pull-down (Fig.4C) were integrated with 224 
the similar data we obtained using n=7 DS-ALL relapse and n=4 DS-ALL remission samples, as well as 225 
n=4 non-DS ALL presentation samples and n=2 non-DS relapse samples. We performed a PCA using 226 
all of these integrated data on N=37 samples from n=31 individual patients, in parallel to the same 227 
readouts from the MUTZ-5 Ph-like ALL reference cell line, and the PCA result was mapped onto a 228 
coordinate system (Fig.5A) using the three principal components (PC1-3, Supplementary-Fig.S6A). 229 
Unsupervised k-means clustering grouped ALL samples into Clusters 1-4 (Fig.5A). This analysis 230 
grouped almost all presentation and remission samples of 9-year event-free survival patients (good 231 
outcome) together into Cluster 1 (green symbols). In contrast, out of 15 samples grouped into 232 
Cluster 2 (red symbols), 13 samples (87%) were from patients with death or subsequent relapse as 233 
outcome. Clusters 3 and 4, further along the PC1-axis, consisted of a small number of exclusively 234 
relapse samples. Using an independent mathematical approach, unsupervised hierarchical clustering 235 
of the 20 DS-ALL presentation samples (Supplementary-Fig.S6E) grouped 90% of the samples into 236 
the same groups as the PCA-mapping. The clustering revealed that presentation samples from 237 
Cluster 1 correlated with good outcome for DS-ALL patients while DS-ALL patients grouped into 238 
Cluster 2 showed a significantly increased risk of relapse (Fig.5B,C). The PCA-derived protein activity 239 
score was independently predictive of outcome (P=.041) (Fig.5C) when analyzed by a multivariate 240 
Cox regression model together with CRLF2 protein-expression, NCI-risk and JAK2-mutation status (or 241 
RAS-mutation status, not shown). Cluster 2 contains a subgroup of DS-ALL presentation samples that 242 
clustered closer to the MUTZ-5 sample (Cluster 3). Like MUTZ-5, these patient samples had high 243 
CRLF2-expression, high JAK2-phoshorylation, and all featured the pattern of high basal RAS-activity 244 
that is TSLP-inducible. An event-free survival analysis that treats these MUTZ-5-like DS-ALL samples 245 
as a separate subcluster indicated a lower median survival (Supplementary-Fig.S6D) but a higher 246 
number of samples is required to reach statistical significance for such subgrouping. 247 
We restricted the further analysis only to DS-ALL primary presentation samples, and quantitatively 248 
compared those that PCA grouped into Cluster 1 (PCA-predicted standard-risk (SR)) to those in 249 
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Cluster 2 (PCA-predicted high-risk (HR)), for the basal activities (Fig.5D top row) and TSLP-induced 250 
activities (Fig.5D bottom row) of pan-RAS, JAK2, STAT5, MEK1/2, ERK1/2 and rpS6. We observed that 251 
basal and TSLP-induced activities of JAK2, ERK1/2 and rpS6 were significantly increased in HR-DS-ALL 252 
presentation samples compared to the SR group (within PCA-Cluster 1). For these proteins, 253 
correlation between risk and protein-activity/inducibility profile for our DS-ALL cohort, resembles 254 
previously reported findings for a different group of HR-ALL, the non-DS Ph-like ALL, grouped by the 255 
presence or absence of CRLF2 rearrangements(27). Additionally, (and this has, to our knowledge, 256 
never been demonstrated for any ALL before), we also observed a significant increase in basal and 257 
TSLP-induced activity of both MEK1/2 and RAS in the HR-DS-ALL group, compared to the SR group. 258 
We also looked at protein expression levels and found RAS and rpS6 levels to correlate with the 259 
high-risk DS-ALL group (Supplementary-Fig.S7A). This provided the rationale to look for differences 260 
in a larger non-DS ALL cohort (see Supplementary Results, Supplementary-Fig.S7B, Supplementary-261 
Fig.S8A, Supplementary-Fig.S8B).  262 
 263 
Our data on primary patient material suggest the compulsory activation of RAS whenever elevated 264 
CRLF2 is present in combination with either mutated or otherwise activated JAK2. This would 265 
eliminate the selective advantage gained by a RAS mutation, explaining the mutual exclusion, 266 
however the underlying molecular mechanism remains to be explained. We therefore sought to 267 
further characterize the molecular mechanism behind the wtRAS activation in these leukemic cells. 268 
 269 
TSLP activates RAS directly and independently of PI3K/mTOR pathway activation 270 
The use of inhibitors on MUTZ-5 cells (Fig.3A) suggested RAS activation to be independent from 271 
blocking of PI3K or JAK pathways. TSLP induction in high CRLF2-expressing and JAK2-mutated B-ALL 272 
is known to activate STAT5 and PI3K/mTOR pathways(27), and this insight is exploited in innovative 273 
new therapeutic approaches that are currently clinically trialed(6). We therefore first confirmed that 274 
our experimental system can reproduce these same results in WB (Supplementary-Fig.S4A). In 275 
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addition, we designed a quantitative method (PLA) to measure rpS6-phoshporylation in individual 276 
cells (Fig.6B). Similar to the TSLP-induction in MUTZ-5 cells, the Ba/F3 CRLF2+JAK2R683G cells also 277 
display an increased rpS6-phosphorylation in PLA compared to cells overexpressing only JAK2R683G 278 
(Supplementary-Fig.S3A). 279 
Downstream effectors of the activated PI3K/mTOR pathway have been shown in some situations to 280 
cross-activate the downstream effectors of RAS-MAPK cascade, and vice versa(28, 29). However, we 281 
observed that immediately upon addition of TSLP (0 min timepoint, Fig.6A) the relative levels of 282 
activated pan-RAS, KRAS, NRAS, PTPN11, MEK1/2, and ERK1/2 were all higher than at any later 283 
timepoint, while in comparison, the activity onset of the PI3K/mTOR downstream target rpS6 was 284 
delayed (Fig.6A). This makes it less likely, at least as the initial effect of TSLP, that the activation of 285 
MEK1/2 and ERK1/2 in such leukemic cells is caused by the cross-talk from the activated PI3K 286 
pathway. As PI3K can also be an effector of RAS(30), we used an alternative biochemical approach 287 
(PLA) by which we demonstrated the ability of a chemical inhibitor of RAS (Salisarib) to block the 288 
TSLP-induced rpS6-activating phosphorylation (Fig.6B, Fig.6C), at a concentration lower than 289 
required to block EIF4EBP1 activity via mTOR-complex destabilization(31). PLA also detected a strong 290 
interaction between RAS and the RBD-containing PI3K-subunit p110α in these cells, which could be 291 
reduced using Rigosertib, a RAS-GTP mimetic that inhibits RAS by binding to the RBD of RAS-292 
effectors (Supplementary-Fig.S2D). 293 
Our data therefore strongly suggest that direct, wtRAS activation can precede, and to a certain 294 
extent promote, the PI3K/mTOR pathway activation in TSLP-induced human ALL cells. 295 
 296 
CRLF2-signaling increases direct interaction between active PTPN11 and RAS 297 
While the PTPN11-inhibitor reduced wtRAS activity in MUTZ5- cells (Fig.3C), the connection between 298 
PTPN11 and RAS in ALL as well as in CRLF2-signaling is unknown. Active PTPN11 is thought to 299 
dephosphorylate RAS to prime it for activation(32), and we found PTPN11 phosphorylation to be 300 
increased by induced CRLF2-signaling (Fig.2A). Furthermore, PTPN11 is published to be in complex 301 
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with JAK2 upon cytokine-induction in tumor cells(33). In order to confirm that the mechanism of 302 
activating RAS in JAK2-mutated B-ALL cells is regulated via PTPN11, we designed a PLA assay that 303 
specifically detects the direct interaction between RAS and phosphorylated PTPN11 (Fig.7A,C). 304 
Indeed, compared to the signal for two cytosolic proteins not expected to interact (PLA negative 305 
control (NC)), a strong PLA signal between RAS and p-PTPN11 was observed and this interaction 306 
almost doubled upon TSLP-induction (Fig.7A). Of note, Ba/F3 cells cultured with IL-3, which activated 307 
RAS (Supplementary-Fig.S1B) and JAK2-phosohorylation, also featured a higher level of RAS and p-308 
PTPN11 interaction in PLA compared to unstimulated cells (Supplementary-Fig.S3B). PLA assays also 309 
detected interactions between SOS1 and GRB2 in these leukemic cells, as well as other direct 310 
interactions involved in RAS activation, which also showed response to CRLF2-activation (RAS and 311 
SOS1; GRB2 and p-PTPN11) (Supplementary-Fig.S2C). Remarkably, blocking PTPN11-activity via the 312 
PTPN11-inhibitor II-B08 reduced both endogenous, and TSLP-induced RAS activity in these cells 313 
(Fig.7B). The PTPN11-inhibitor did not reduce the phosphorylation marker on PTPN11 itself (Fig.7B) 314 
but disrupted the direct interaction between RAS and p-PTPN11, lowering it to levels below those in 315 
uninduced cells (Fig.7C). Furthermore, a cytotoxic assay showed leukemic cell viability to be reduced 316 
by the PTPN11-inhibitor, similarly as with the RAS-inhibitor (Fig.7D). Taken together, these results 317 
show that the mechanism of wtRAS activation by CRLF2 signaling depends on its direct interaction 318 
with catalytically active PTPN11. 319 
 320 
Primary DS-ALL patient biopsies from high-risk sub-cohorts have a potent response to RAS-321 
inhibition in vitro as a distinguishing feature  322 
We used primary surplus clinical material in Fig.5 from n=31 patients. Out of these, we had enough 323 
primary diagnosis material for 13 patients (before any therapy) to measure the effects of RAS, PI3K, 324 
or JAK inhibitors on individual pathway activation status in the presence of TSLP. The efficacy of RAS 325 
inhibition on intracellular protein activity (expressed as panRAS activity ratio between inhibitor and 326 
vehicle treated samples) for primary presentation samples showed a significant difference (P=.021 327 
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by Fisher’s exact test) between the good outcome (n=7) and poor outcome DS-ALL groups (n=6) 328 
(Fig.8A). Also, samples in which RAS can be further activated by TSLP were more sensitive to RAS 329 
inhibitor treatment (Supplementary-Fig.S9). For all poor outcome DS-ALL primary presentation 330 
samples, inhibitions of individual pathway effector activities via the RAS, PI3K, or JAK inhibitors was 331 
visualized as inverted bar graph ranging from 0% (no inhibition) to 100% (complete inhibition) 332 
(Fig.8B). As indicated by red P-values, PI3K inhibitor significantly inhibited rpS6 phosphorylation, 333 
whereas JAK inhibitor significantly inhibited ERK, rpS6, and STAT5 phosphorylation. Notably, these 334 
inhibitors did not have any significant effect on RAS activity, reproducing the result obtained for the 335 
MUTZ-5 Ph-like ALL cell line (Fig.3A). Only the RAS inhibitor was able to significantly block RAS 336 
activation in poor outcome DS-ALLs (Fig.8B), in addition to blocking rpS6 phosphorylation, as 337 
likewise shown for the MUTZ-5 cells (Fig.6B and Fig.3B). This suggests that only RAS-inhibitor action 338 
is capable of efficiently blocking RAS activation in cells from both Ph-like/non-DS and DS-ALL poor 339 
outcome patient samples at the point of first clinical presentation, irrespective of the presence of 340 
RAS mutation. In contrast, JAK and PI3K inhibitor treatments alone did not significantly impact RAS 341 
activity in these samples (Fig.8B).  342 
In order to better understand the physiological/therapeutic relevance, we measured the effect of 343 
RAS-inhibition on cell viability in 6 DS-ALL primary presentation samples (Fig.8C). The competitive 344 
RAS-inhibitor Rigosertib was chosen over Salisarib as Rigosertib shows more potential in current 345 
clinical trials and still can disrupt both wtRAS and mutant-RAS signaling activity. Remarkably, after 7 346 
days the RAS-inhibitor treatment had significantly reduced the viable cell count (almost halved 347 
compared to vehicle-control) in almost all 6 samples, independent of RAS-mutation status (Fig.8C). 348 
Only in one patient sample (DS17) the RAS inhibitor needed a combinatorial-treatment (adding JAK-349 
inhibitor) to achieve a similar reduction of viable cells. Cells of this patient treated separately with 350 
PTPN11-inhibitor resulted in a significantly reduced viable cell count (Fig.8D). 351 
The JAK-inhibitor alone showed no statistically significant effect in any of the DS-ALL samples, similar 352 
to what was observed for MUTZ-5 (Fig.3A). Interestingly, while the PI3K/mTOR-inhibitor and the 353 
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RAS-inhibitor both showed effective reduction of viable cells in all 3 samples (DS16, DS20, DS27) that 354 
were clustered by PCA as SR (Fig.5), only RAS-inhibition was able to reduce the viable cell count in 355 
the samples grouped by the PCA (Fig.5) as HR (DS09, DS17, DS23) (Fig.8C). 356 
These results suggest a paradigm shift in precision-therapy approach, by identifying HR sub-groups 357 
that are unlikely to respond to PI3K- or JAK-inhibitors alone and require direct RAS-inhibition. 358 
Importantly, the data confirm the notion that wtRAS-inhibitors could provide a uniform treatment 359 
for both mutated and activated wtRAS cases (encompassing up to 80% of DS-ALL).  360 




Both DS-ALL and Ph-like ALL share CRLF2-rearrangements and various kinase-activating alterations 362 
as potential targets for individualized therapy using specific kinase-inhibitors(8, 34). This lead to the 363 
use of phosphorylation patterns of individual kinase signaling cascades as informative biomarkers for 364 
combinatorial therapy design(6, 16, 35).  365 
In DS-ALL, recent studies of sub-clonal and single-cell evolution of changes in leukemic ALL blasts 366 
have identified signaling activators (CRFL2-rearrangements, JAK2 mutations, RAS-MAPK mutations 367 
and iAMP21) as frequent events in primary and relapsed leukemic blasts(20, 21, 36). In particular, 368 
JAK2 and RAS mutations were found to be both acquired and lost in relapse samples in a mutually 369 
exclusive manner(20, 21). This emphasizes the need for individualized combined-therapy 370 
approaches that have a better chance of preventing the selection of sub-clones driven by a different 371 
signaling. Our data show that elevation in CRLF2 levels combined with JAK2 activation are sufficient 372 
to activate wtRAS, and that TSLP has the potential to induce the wtRAS activity, independently of the 373 
PI3K/mTOR activity. This has implications on the choice of the combinatorial therapy design. 374 
Remarkably, our combined data from exome sequencing(20), and primary ALL cell protein signaling 375 
(presented in this study), suggest that up to 65-82% of DS-ALL cases have highly activated RAS, either 376 
constitutively, or upon TSLP induction, regardless of their mutation profiles. 12 of 14 cases with high 377 
RAS-activity featured either RAS mutations or high CRLF2/JAK2 signaling (including JAK2-mutations). 378 
The only two samples featuring high wtRAS activity in absence of high JAK2 phosphorylation levels 379 
might activate RAS via a different pathway yet to be uncovered for DS-ALL. A very recent novel 380 
patient-derived xenograft models for DS-ALL found CBL-mutant (wtRAS) cells to have as high ERK1/2-381 
phosphorylation as KRAS-mutant cells(37). Interestingly in the same study, the leukemia burden in 382 
both wtRAS(JAK2-mutant) and mutant-RAS xenograft models was reduced via MEK-inhibitor, 383 
representing a strongly corroborating evidence to some of the conclusions of our study. 384 
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Taking RAS activity and inducibility, integrated with other protein activation patterns, we performed 385 
a multivariate analysis clustering that identified SR and HR groups for DS-ALL and showed that 386 
protein activation pattern is independently predictive of outcome using multivariate Cox regression.  387 
Ultimately, patient-specific inhibitor combinations based on analyzed pathway activities should be 388 
part of future precision medicine approaches for HR-ALL groups. Ph-like ALL patients are already 389 
being studied for the combined effects of PI3K/mTOR and JAK/STAT inhibitor treatment(6). 390 
“Supplementary Discussion” contains an expanded discussion on RAS-inhibitor strategies. 391 
Compared to RAS, mutations in PTPN11 are less prevalent in DS-ALL but mutations in JAK2, RAS, and 392 
PTPN11 also appear to be mutually exclusive throughout different types of childhood ALL (20, 22, 38, 393 
39). Our data reveal that reducing RAS activity via inhibition of PTPN11 catalytical action may 394 
provide a functional alternative for ALL cells, while blocking the phosphorylation of PTPN11 via JAK 395 
inhibitors was not sufficient to prevent RAS activity, and concordantly with our mechanistic insight 396 
was also unable to block the direct interaction between PTPN11 and RAS. Our findings suggest that, 397 
depending on the patient’s protein activity profile, RAS inhibition (upstream, direct, or downstream) 398 
should be considered in combination with PI3K/mTOR and/or JAK/STAT inhibitors to further 399 
augment clinical treatment. In particular in DS-ALL, RAS/MAPK-inhibition might be applicable to 400 
most HR patients, as we show that specifically samples stratified by our PCA analysis as HR seemed 401 
resistant to treatment with PI3K/mTOR or JAK inhibitors alone while only RAS-inhibition slashed the 402 
viable cell count in half. However, based on our data, the focus should not lie on targeting mutant-403 
RAS alone but also the inhibition of overstimulated wtRAS pathway activity in absence of RAS 404 
mutations. 405 
Childhood leukemia in DS is distinguished by a relatively specific pattern of acquired mutation 406 
changes, for both AML(40-45) and ALL(20, 21, 46), and the reasons for this are not fully explained.  407 
More generally, people with DS have an unusual epidemiological pattern of malignancy: increased 408 
incidence and mortality for childhood leukemias of all types, but much decreased childhood and 409 
adult solid tumors(47, 48). Functional consequences of an increased dose of some chromosome 21 410 
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genes may play important roles(48), and this is discussed in greater detail in “Supplementary 411 
Discussion”. It will be important to unravel the mechanisms behind the actions of these 412 
chromosome 21 genes, as their specific inhibition may be an additional component to consider in 413 
combinatorial therapy approaches(37, 49). This is highlighted by very frequent observations of extra 414 
copies of chromosome 21 as acquired changes in DS and non-DS ALL, both at diagnosis, and at 415 
relapse(20, 50). 416 
 417 
In conclusion, our data show that activation of RAS protein is a common feature of up to 80% of DS-418 
ALL, suggesting inhibition of overstimulated RAS pathway activity should be a unifying therapeutic 419 
strategy, even in the absence of RAS mutations. Importantly, our data indicate that patient pre-420 
stratification for therapy optimization should assess RAS/MAPK protein activation status. 421 
 422 
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Fig.1) Combination of CRLF2 overexpression and constitutively active JAK2 is sufficient for wt RAS 563 
activation. WB analysis of the murine pro B cell line Ba/F3. Cells were stably transfected with human 564 
JAK2R683G and/or human CRLF2 (see Supplementary-Fig.S1C and Supplementary-Fig.S1D) and 565 
cultured in IL-3-containing medium. All cells were then starved from IL-3 and cells were lysed. Each 566 
cell lysate was split up for analysis in RAS-GTP pull-down assay and for total proteins. An SDS-PAGE 567 
followed by WB was performed.  568 
(A) Left-hand side blot shows the RAS-GTP (activated RAS) pull-down while the right-hand side blots 569 
show whole cell lysates of the same samples. Antibody-targets are labeled on the right side of each 570 
image with black arrows marking the respective protein band; the antibody against HA-tag shows 571 
the expression of the human JAK2 construct. The experiment was repeated 4 times independently. 572 
(B) Quantification of (A) for active RAS (RAS-GTP) normalized to its level in untransfected cells. Error 573 
bars are SD and P-values were determined in one-way ANOVA and post-hoc Bonferroni multiple 574 
comparison. 575 
 576 
  577 
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Fig.2) Human Ph-like B-ALL (spontaneous CRLF2-rearrangment and JAK2R683G-mutation) cells 578 
activate wtRAS and RAS-interacting proteins upon TSLP-induction. MUTZ-5 cells were stimulated 579 
with 20 ng/mL hTSLP (maximal effective TSLP-concentration, Supplementary-Fig.S4B) for 10 min 580 
before lysis. Each lysate was split up for analysis in RAS-GTP pull-down assay and for WB.  581 
(A) An SDS-PAGE followed by WB was performed. To assess the total protein and phosphorylated 582 
protein amounts on the same PVDF-membrane, each membrane part was stripped and reprobed 583 
with new antibodies. RAS-GTP pull-down blots are on the left side while the right-hand side blots 584 
show whole cell lysates of the same samples. The grey arrow shows the unspecific signal of the GST-585 
RAS binding domain (RBD) used in the active RAS pull-down assay acting as a loading control. The 586 
experiment was repeated 5 times independently and the graphs show the quantification for active 587 
RAS (RAS-GTP), phospho-MEK1/2, phospho-JAK2, and phosho-PTPN11. Beta-actin and total protein 588 
signals were used as a loading control to normalize samples. 589 
(B) A blot separate from (A) demonstrates the TSLP-inducibility of RAS-effector bRAF. 590 
(C) Quantification of 5 independent ELISA experiments in which RAS-GTP in MUTZ-5 cells was 591 
measured using a different, ELISA-specific active-RAS pull-down assay. 592 
(D) MUTZ-5 cells were probed for the activation of KRAS-GTP, HRAS-GTP, or NRAS-GTP isoforms (left 593 
side). The blots on the right show the total expression of the respective RAS proteins and the graphs 594 
show the average signal fold-change for KRAS-GTP, HRAS-GTP and NRAS-GTP (N=4, means ±SD). P-595 
values were calculated using Student’s T-test and adjusted with a Bonferroni-correction for 596 
sequential multiple-comparison. 597 
(E) Whole, non-denatured lysate from uninduced or TSLP-induced MUTZ-5 cells was subjected to an 598 
antibody-microarray. The graph shows relevant, most statistically significant changes in protein-599 
phosphorylations, a heatmap-overview for all analyzed protein-phosphorylations can be found in 600 
Supplementary-Fig.S4C. (N=6, means±SD). P-values were calculated using Student’s T-test 601 
(Bonferroni-correction for sequential multiple comparison can be found in Supplementary-Tab.S2). 602 
Protein activity-based risk stratification of DS-ALL 
27 
 
Fig.3) Inhibition of RAS stops wt-RAS sequence Philadelphia-like ALL cell growth in the presence of 603 
TSLP. (A) MUTZ-5 cells were seeded at 6.5×105/mL density and cultured over 4 days with either 0.5% 604 
DMSO (vehicle control), 50 µM Salirasib (indirect Pan-RAS inh.), 10 µM PI-103 (PI3K/mTOR dual inh.), 605 
or 5 µM Ruxolitinib (JAK inh.), each in absence or presence of 20 ng/mL human TSLP. Cell count and 606 
viability was determined in an NC-250 automated cell counter daily. The stacked-bar graph on the 607 
left side shows the growth rate after the 90 hrs timepoint, averaged from 2 independent 608 
experiments, each with triplicate wells. Red error bars are SD from the dead cell fraction while the 609 
black error bars show the SD of the viable cells. P-values were calculated in one-way ANOVA from 610 
the total cell growth rate and adjusted in a post-hoc Bonferroni multiple comparison. Only relevant 611 
P-values are shown in the graph, for a complete list see Supplementary-Tab.S2. 612 
(B) The graph shows the cell viability of the experiment in (A) over time. 613 
(C) MUTZ-5 cells were pre-treated for 2 hrs with either 0.5% DMSO (vehicle control), 10 µM PI-103 614 
(PI3K/mTOR dual inh.), 50 µM Salirasib (indirect pan-RAS inh.), 5 µM Ruxolitinib (JAK inh.), 50 µM 615 
Vemurafenib (Pan-Raf inh.), or 25 µM II-B08 (PTPN11 inh.), and then stimulated with 20 ng/mL 616 
human TSLP for 10 min followed by cell lysis. Each lysate sample was split up for analysis in RAS-GTP 617 
pull-down assay and for total protein signal. RAS-GTP pull-down (left) and lysate samples (right) 618 
were loaded on separate gels. An SDS-PAGE followed by WB was performed. To assess the total 619 
protein and phosphorylated protein amounts on the same PVDF-membrane, membranes were 620 
stripped and reprobed with new antibodies. Antibody-targets are labeled on the right side of each 621 
image with black arrows indicating the respective protein band. 622 
(D) MUTZ-5 cells were treated with 50 µM Salirasib (pan-RAS-inhibitor), 10 µM PI-103 (PI3K/mTOR 623 
dual inhibitor), or 5 µM Ruxolitinib (JAK-inhibitor) like in (C) after which the RAS-GTP levels were 624 
measured in ELISA. N=3 independent experiments, bar graph shows means±SD. 625 
(E) MUTZ-5 cells were treated as in (D) and STAT5 activity was determined via Western blot. N=3 626 
independent experiments, bar graph shows means±SD. P-values for (D, E) were calculated in one-627 
way ANOVA and post-hoc Bonferroni multiple comparison.  628 
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Fig.4) 70% of primary DS-ALL presentation samples show activated and/or TSLP-inducible RAS, 629 
regardless of mutation-status. Primary presentation samples of DS-ALL patients were cultured for 2 630 
days (detailed in Supplementary-Fig.S5A-legend) and then induced for 10 min with 20 ng/mL TSLP 631 
(or uninduced) in serum-reduced medium. 632 
(A) Each lysate was split up for RAS-GTP pull-down assay (left blot) and for standard WB (right blot). 633 
Grey arrow shows the loading of the GST-RBD in the pull-down assay. 634 
(B) The RAS activity pattern in the patient samples from (A) was confirmed via ELISA measurement of 635 
RAS-activity in aliquots that were independently thawed and processed. 636 
(C) Overview of the ELISA-measured RAS activity for the DS-ALL cohort at diagnosis (not enough cell 637 
material was available for DS26, DS29, and DS30). The RAS-GTP pull-down ELISA was performed on 638 
lysates (100 ng/μL total-protein) from cells at minimum 75% viability. Brackets on top indicate the 639 
four RAS activity patterns presented in (A, B). For visualization purposes only in this graph, basal 640 
RAS-activity over 0.5 (median of all patient samples) MUTZ-5 basal RAS activity was grouped as high 641 
RAS activity while an increase by at least 10% RAS-GTP in TSLP-stimulated samples over uninduced 642 
samples in ELISA was classed as TSLP-inducible RAS. For visualization, JAK2-phosphorylation levels 643 
measured in WB were categorized as –(negative)=0.00-0.05; +=0.05-0.50; ++=0.50-1.00; +++=1.00-644 
2.00, and CRLF2 protein-levels were categorized as –(negative)=0.00-0.05; +=0.05-0.20; ++=0.20-645 
0.50; +++=0.50-1.50. None of these arbitrary threshold-groupings were used in the clustering 646 
analysis (Fig.5). Known CRLF2-rearrangements are marked (R). All values are normalized to those 647 
measured for uninduced MUTZ-5 cells processed in parallel to patient cells. Table boxes: Outcome of 648 
leukemia (white = good outcome, black = poor outcome), RAS mutations (=blue) or JAK2 mutations 649 
(=red) (grey=unsequenced). For patient/sample groups other than DS-ALL-diagnosis (Non-DS (NDS) 650 
at presentation, DS complete remission (CR), and DS/NDS at relapse) only averages are shown. For 651 
an overview of the WB data and analyzed protein expression/phosphorylation of all individual 652 
samples, see Supplementary-Fig.S5. 653 
 654 
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Fig.5) Sub-stratification of DS-ALL patients based on primary cells: RAS-activation and downstream 655 
signaling in relation to standard-therapy outcomes. (A) A PCA was performed on the quantified 656 
data of Fig.4 (data was given as continuous variables; no cutoffs nor pre-groupings were used) for 657 
the DS-ALL cohort at diagnosis, and (where available) at remission, and relapse, as well as 658 
presentation and relapse samples from Non-DS ALL patients. Top view of the PCA-mapping for all 6 659 
analyzed protein-activities (basal and TSLP-induced) as well as CRLF2-protein expression of all 660 
samples along the calculated principal components (see also Supplementary-Fig.S6A). K-means 661 
unsupervised clustering (with k set to 4 to achieve minimal class-class deviation, Supplementary-662 
Fig.S6B) grouped samples into clusters 1 to 4 (listed in Supplementary-Fig.S6C). 663 
(B) PCA Clusters 1 and 2 contain all samples of the DS-ALL diagnosis cohort and were analyzed 664 
according to their outcome: A Fisher’s exact test determined the P-value between the number of 665 
good and poor outcomes between the two clusters (bar graph).  666 
(C) Kaplan–Meier curves of cluster 1 (SR = standard risk) and cluster 2 (HR = high risk) DS-ALL 667 
patients. Table show a Cox proportional-hazards model for protein activity score (PCA-derived 668 
principal component from all quantified protein activities at basal and TSLP-induced level) together 669 
with CRLF2-protein expression level (for CRLF2+ samples), NCI risk groups (SR: age at diagnosis 1-10 670 
yrs and WBC < 50.000/µL; HR = children age > 10 yrs and/or WBC > 50.000/µL; or unknown), and 671 
presence of activating JAK2-mutations. Reverse Kaplan-Meier median follow-up for N=20 DS-ALL was 672 
18.4 years. Patient numbers at risk for each year are given in the table. 673 
(D) The means of all analyzed basal or TSLP-induced protein activities are compared between the SR 674 
group (DS-ALL patients in PCA cluster 1) and the HR group (DS-ALL patients in PCA cluster 2). All error 675 
bars are SD; P-values were calculated using Student’s T-test and are adjusted with a Bonferroni-676 
correction for sequential multiple comparison. 677 
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Fig.6) Direct wtRAS-activation can precede PI3K/mTOR-pathway activation and resulting PI3K-679 
downstream signaling activity was blocked by RAS inhibitor. (A) Effect of TSLP induction over time. 680 
MUTZ-5 cells were incubated with 20 ng/mL human TSLP at 37 °C for the indicated time points (0 681 
min to 18 hrs) before cell lysis. Due to the centrifugation step the TSLP can act for 5 min before lysis 682 
at timepoint 0. Each cell lysate was split up for RAS-GTP pull-down assay and WB. RAS-GTP pull-683 
down elutions are on the left side while the right-hand side blots show whole cell lysates of the same 684 
samples. Antibody-targets are labeled on the right side of each image with black arrows indicating 685 
the respective protein band.  686 
(B) Activation of PI3K/mTOR downstream target rpS6 protein was monitored via PLA in high-687 
throughput microscopy. MUTZ-5 cells were either not induced or induced with 20 ng/mL TSLP for 10 688 
min. Where indicated, cells were pre-treated for 3 hrs with either DMSO (vehicle control), RAS 689 
inhibitor, or JAK inhibitor. Cells were fixed and permeabilized in a 96 well plate. After blocking, 690 
antibodies against phosphorylated rpS6 and total rpS6 were used in conjunction with PLA rabbit and 691 
mouse probes to allow specific readout of rpS6 activation in single cells in a high-throughput 692 
manner. Histograms show the distribution for a single experiment of the number of PLA spots in cells 693 
with at least 1 PLA spot (assay control is only shown in the bar graph). A minimum of 600 cells were 694 
analyzed per sample. Non-linear Gaussian fitting curves were plotted. Fluorescent microscope 695 
images show examples of PLA spots in MUTZ-5 cells for the respective treatment; white scale bars 696 
are 20 µm long.  697 
(C) The bar graph summarizes the average PLA spot counts of 3 independent experiments. Error bars 698 
are SD and P-values were determined in one-way ANOVA and post-hoc Bonferroni multiple 699 
comparison. 700 
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Fig.7) CRLF2-signaling induces direct interaction between activated PTPN11 and RAS, and PTPN11-702 
activity is required for ALL cell growth. (A) Direct interaction between RAS and phosphorylated 703 
PTPN11 was monitored via PLA using high-content microscopy. Serum-starved MUTZ-5 cells were 704 
induced (or not) with 20 ng/mL TSLP for 10 min. Cells were fixed and permeabilized in a 96 well 705 
plate. Antibodies against phosphorylated PTPN11 and pan-RAS were used in conjunction with PLA-706 
probes to allow the amplification and staining of interaction-specific PLA-spots. The negative control 707 
(NC) are two cytosolic proteins not expected to interact. Fluorescent-microscopy images show 708 
examples of PLA-spots (scale bars = 20 µm). At least 250 cells per well were analyzed using Operetta-709 
CLS automated high-content microscopy platform. The bar-graph shows the averages of 3 710 
independent experiments (each performed in triplicates). Error bars are SD and P-values were 711 
determined in one-way ANOVA and post-hoc Bonferroni multiple comparison. 712 
(B) MUTZ-5 cells were pre-incubated with DMSO or 25 µM II-B08 (PTPN11 inhibitor) for 2 hrs and 713 
then stimulated or not with 20 ng/mL TSLP for 10 min before cell lysis. Each cell lysate was split up 714 
for RAS-GTP pull-down assay and for WB (whole-cell lysates). 715 
(C) MUTZ-5 cells were treated as in (B) before fixation. A PLA described in (A) was performed. 716 
(D) MUTZ-5 cells were seeded at 1.6×105/mL density and cultured for 7 days with either 0.5% DMSO 717 
(vehicle control), 50 µM Salirasib (indirect pan-RAS inhibitor), 25 µM II-B08, 50 μM Vemurafenib 718 
(pan-Raf inhibitor), 1 μM PD0325901 (MEK1/2-inhibitor), or 5 µM Ruxolitinib (JAK-inhibitor), in 719 
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Fig.8) RAS-inhibitor blocks RAS-activity with greater efficiency in primary, poor outcome DS-ALL 726 
patient samples, prior to relapse.  727 
(A) Efficacy of RAS-inhibitor on ELISA-measured RAS-activity in DS-ALL, compared by outcome. 728 
Primary presentation DS-ALL samples were cultured for 2 days (detailed in Supplementary-Fig.S5A-729 
legend). Samples with sufficient cell count were treated with 0.5% DMSO (vehicle-control), or 50 µM 730 
Salirasib (indirect pan-RAS-inhibitor) for 3 hrs, and then induced for 10 min with 20 ng/mL TSLP in 731 
serum-reduced medium. Cells were lysed for RAS-GTP pull-down assay and whole-lysate WB 732 
(Supplementary-Fig.S5A). Protein-activities of inhibitor-treated TSLP-induced samples were 733 
normalized to the activity-level of the respective vehicle-treated TSLP-induced samples. If inhibitor-734 
treatment reduced the RAS-activity by over 10% compared to vehicle-control (dashed-line), the 735 
sample was tallied as successful RAS-blocking. A Fisher’s exact test was performed between the 736 
groups. Good outcome: N=7 (3 RAS-mutations, 1 JAK2-mutation); poor outcome: N=6 (1 JAK2-737 
mutation). 738 
(B) Waterfall-plot shows the mean efficacies of 50 µM Salirasib, 10 µM PI-103 (PI3K/mTOR dual-739 
inhibitor), or 5 µM Ruxolitinib (JAK-inhibitor) on pathway components (0%=no effect, 100%=full 740 
block of TSLP-induced protein-activation); tested on primary presentation samples from poor 741 
outcome DS-ALL patients in (A). Error bars are SD; black P-values were determined in one-way 742 
ANOVA with post-hoc Bonferroni multiple-comparison. The red P-values (Bonferroni-corrected for 743 
sequential multiple-comparison) indicate if each inhibitor on average significantly reduced the 744 
respective protein-activity in these samples (only P < 0.05 shown; Supplementary-Tab.S2 lists all P-745 
values). 746 
(C) Cell-toxicity effect of inhibitors in DS-ALL. Samples from 6 patients were cultured for 2 days like in 747 
(A) before seeding 8×105 viable cells/mL in IMDM-complete medium (without IL-3/IL-7 but 748 
containing 20 ng/mL TSLP) together with 0.5% DMSO, 30 µM Rigosertib (non-ATP competitive RAS-749 
GTP inhibitor), 10 µM PI-103, 5 µM Ruxolitinib, or Rigosertib&Ruxolitinib (DS23 cell count was 750 
insufficient). After 7 days, cell count and viability were measured (N=3, means±SD); vehicle-control 751 
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cell numbers reduced to 1-4×105/mL, 70-90% viability. P-values were determined in one-way ANOVA 752 
with post-hoc Dunnett's multiple-comparison (all treatments compared to DMSO-control). 753 
E) 8×105 viable cells/mL of patient-DS17 were handled like in (C) and treated with 0.5% DMSO, or 25 754 
µM II-B08. After 7 days, cell count and viability were measured (N=3, means±SD); average vehicle-755 
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Supplementary Material and Methods 
 
Antibodies, inhibitors, and cytokines 
The primary antibodies against β-actin (Cat.#ab8227; WB (WB)1:10,000) and GRB2 (Cat.#ab86713; 
PLA 1:100) were purchased from Abcam (Cambridge, UK); the antibody against CRLF2 (Cat.#AF981; 
WB 1 µg/mL) was purchased from R&D Systems (Minneapolis, US). The primary antibodies against 
pan-RAS (Cat.#8832; WB1:200), phospho-bRAF (Cat.#2696; WB1:1,000, PLA1:100), JAK2 (Cat.#3230; 
WB1:900), HA-tag (Cat.#2367; WB1:1,000), MEK1/2 (Cat.#8727; WB1:1,000), phospho-MEK1/2 
(Cat.#9154; WB1:1,000), RPS6 (Cat.#2317; PLA1:50, WB1:1,000) and phospho-STAT5 (Cat.#4322; 
WB1:1,000), phospho-JAK2 (Cat.#3771; WB1:1,000), ERK1/2 (Cat.#9102; WB1:1,000), phospho-
ERK1/2 (Cat.#9101; WB1:1,500), GRB2 (Cat.#3972; WB1:1,500), phospho-RPS6 (Cat.#2211; PLA1:50, 
WB1:1,000), PI3Kp110α (Cat.#4249; PLA 1:100), SOS1 (Cat.#5890; PLA 1:100), PTPN11 (Cat.#3752; 
WB1:1,000, PLA1:100), phospho-PTPN11 (Cat.#3751; WB1:1,000, PLA1:100), and STAT5 (Cat.#9363; 
WB1:1,000) were purchased from Cell Signaling Technology (Danvers, US). The primary antibodies 
raised against KRAS (Cat.#sc-30; WB1:180), NRAS (Cat.#sc-31; WB1:160) and HRAS (WB1:170) were 
bought from Santa Cruz Biotechnology (Dallas, US). The primary antibodies used in 
immunofluorescence against pan-RAS (Cat.#MA1-012; IF1:100, PLA1:100) and bRAF (Cat.#PA5-14926; 
IF1:50, PLA1:50, WB1:1,000) were purchased from ThermoFisher Scientific (Waltham, US), as was 
SOS1 (Cat.#MA5-17234; PLA1:100). 
Secondary HRP-conjugated antibodies against mouse (Cat.#ab97023; WB1:8,000), rabbit 
(Cat.#ab97051; WB1:9,000), or goat (Cat.#ab97100; WB1:7,000) IgG species were obtained from 
Abcam. The secondary fluorescent antibodies anti-mouse IgG Alexa Fluor 488 (Cat.#A11029) and  anti-
rabbit IgG Alexa Fluor 594 (Cat.#A11037) were purchased from ThermoFisher Scientific. 
The small molecule inhibitors PI-103 (PI3K/mTOR-inh.; Cat.#S1038), Ruxolitinib (JAK-inh.; Cat.#S1378), 
Salirasib (RAS-inh.; Cat.#S7684), Rigosertib (RAS-signaling-inh.; Cat.# S1362), PD0325901 (MEK1/2-
inh.; Cat.#: S7684), and Vemurafenib (RAF-inh.; Cat.#S1267) were purchased from Selleck Chemicals 
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(Houston, US). Additionally, the PTP inhibitor XXXI/II-B08 (PTPN11-inh.; Cat.#565852; EMD Millipore, 
Burlington, US) was purchased. All inhibitors were reconstituted in dimethyl sulfoxide (DMSO; 
Cat.#D2650; Sigma-Aldrich, St. Louis, US). 
The cytokine used for Ba/F3 culturing was 10 ng/mL murine IL-3 (Cat.#31310-03-10; Gold 
Biotechnology, St Louis, US). 
 
SDS-PAGE and WB 
Protein lysates (see “RAS activity assays”) were mixed with 4×Laemmli buffer (Cat.#161-0747; Bio-Rad 
Laboratories, Hercules, US) containing fresh 200 mM DL-Dithiothreitol (Cat.#3483-12-3; Sigma-
Aldrich). For most samples 5 µg total protein could be loaded. SDS-PAGE with 11%-resolving/5%-
stacking acrylamide gels, and WB on PVDF-membrane (Cat.#88518; ThermoFisher Scientific) were 
performed according to the standard protocol of the equipment-manufacturer (Bio-Rad Laboratories). 
Each PVDF-membrane piece (per antibody) was separately imaged via the auto-exposure function of 
the ChemiDoc-MP imaging system (Bio-Rad Laboratories). Supplementary-Fig.S5B legend describes 
the WB-signal quantification in detail. PVDF membranes were stripped from antibodies using the 
Restore WB-Stripping buffer (Cat.#21059; ThermoFisher Scientific). 
 
Proximity ligation assay (PLA) 
MUTZ-5 cells at 1×106 cells/mL density were either not induced or induced with 20 ng/mL TSLP for 10 
min. Where indicated, cells were pre-treated with either DMSO (vehicle control), RAS inhibitor, or JAK 
inhibitor for 3 hrs. Cells were fixed in 4% PFA in a 96-well plate for 15 min during which the plate was 
centrifuged at 400×g. Cells were permeabilized with methanol at -20 °C for 5 min. After blocking with 
5% FBS, primary antibodies were incubated over night at 4 °C. On the next day, rabbit and mouse 
probes from the Duolink In Situ Orange kit (Cat.#DUO92102; Sigma-Aldrich) or the Duolink flowPLA 




Operetta CLS high-content screening microscope (PerkinElmer, Waltham, US) were used to detect and 
count the fluorescent PLA spots in at least 600 single cells for each well and condition. Spot distribution 
histograms and non-linear Gaussian fitting curves were plotted in Prism v8.1 (GraphPad Software, San 
Diego, US). 
 
Principal component analysis (PCA) 
ELISA and quantified WB data for all 38 samples successfully analyzed for this study were fed into the 
multidimensional vectoral data visualization software ViDaExpert v1.2(1). The 13 variables included 
for the PCA calculations were: pan-RAS, JAK2, STAT5, MEK1/2, ERK1/2, and rpS6 activity levels in 
absence or presence of TSLP as well as CRLF2 protein expression. Eigenvector-based multivariate 
analysis was performed and the contributions of the principal components 1-3 (PC1-3) of each original 
variable were calculated (Supplementary-Fig.S6A). Data was transformed to a new 3D coordinate 
system using the projection of PC1-3. For the k-means clustering of the patient samples, k was set to 
4 after identifying the smallest, significantly different class-class deviation for k (Supplementary-
Fig.S6B). The resulting coordinate system was loaded into Adobe Illustrator software for presentation. 
The heatmap was generated in R-software 3.6.0 (The R Foundation, Vienna, AT) by performing 
unsupervised hierarchical Ward’s clustering algorithm on the DS-ALL presentation samples (using the 
same variables of the PCA), with correlation coefficient as distance metric. 
 
Statistical analysis 
For all multiple comparison analysis, one-way ANOVA and post-hoc Bonferroni calculations were 
performed in Prism v8.1. When only two samples were compared, a two-tailed, unpaired student t-
test was performed. For each series of experiments that are not independent, an additional Holm-
Bonferroni correction was carried out to adjust the P-values for sequential multiple comparison. All 
replicate experiments were handled and measured independently. 
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Kaplan–Meier survival estimator plots and multivariate analysis using Cox proportional-hazards model 
were calculated in R-software 3.6.0, for details on the used factors see the respective figure legends. 
Variable/category candidates stated in the respective figures were included because they were either 
the respective analyzed protein/mutation/activity or are known general ALL prognostic markers. 
 
Phospho-protein antibody-microarray 
MUTZ-5 cells were serum-starved for 16 hrs at 1×106 cells/mL density before being induced with 20 
ng/mL TSLP (or uninduced)  for 10 min at 37 °C. 8×106 cells per condition were lysed in 110 µL 
Extraction Buffer from the microarray assay kit (Cat.#KAS02; FullMoon BioSystems, Sunnyvale, USA). 
The antibody-microarray assay was performed according to the manufacturer’s protocol and the 
native, Cy3-labeled proteins were allowed to bind to the antibody-microarray slides (Cat.#PJS202; 
FullMoon BioSystems). The slides were scanned using the Operetta CLS microscope and the spots for 
the 202 individual antibodies were analyzed using Protein Array Analyzer software v1.1.c in ImageJ. 
Each signal was normalized to the Cy3-control present on each microarray slide. To exclude changes 
that are due to epitope-obstruction from bound protein partners, the signal for phosphorylation-site-
specific antibodies was normalized to the signal from each corresponding total antibody raised against 
the same (unphosphorylated) peptide sequence. Background was set as the average signal from BSA-
spots (empty). 
 
Ba/F3 cells transduction 
Ba/F3 cells were nucleofected using a Nucleofector 2b (Lonza, Basel, CH) using Cell Line Nucleofector 
Kit V (Lonza) according to the manufacturer’s protocol. The plasmids used for Ba/F3 transfection were 
MSCVpuromycinR-hCRLF2 (human wt CRLF2) and MSCVneomycinR-hJAK2RG (human JAK2R683G 
mutant)(2). In order to select for stably transfected cells, MSCVpuromycinR-hCRLF2-transfected cells 
were cultured with 1 µg/mL puromycin (Cat.#P8833; Sigma-Aldrich), MSCVneomycinR-hJAK2RG-
transfected cells were cultured with 1.8 mg/mL G418 (Cat.#108321-42-2; Sigma-Aldrich), and co-
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transfected cells were cultured with both antibiotics together. Cells transfected with the plasmid 
pMax-EGFP (Lonza) were used as control. 
 
DNA- and RNA-sequencing of primary patient material 
Patient samples were either whole exome-sequenced previously(3) or amplicons of JAK2, KRAS and 
NRAS (in addition, HRAS of MUTZ-5 cells) were amplified from genomic DNA and sent for Sanger 
sequencing (1st BASE, Singapore, SG) in both orientations and screened for mutations in Mutation 
Surveyor v5.0.1 (Softgenetics, State College, US). Oligonucleotides (Supplementary-Tab.S3) were 
designed to cover known activating mutation hotspots. 
RNA sequencing was performed for patients of the MS2003/2010 studies(4, 5) using TruSeq Stranded 
mRNA Library Prep kit (Illumina, San Diego, US); sequenced on HiSeq2000/2500 or NextSeq500 
(Illumina). Reads were aligned to hg19-reference genome using Tophat2(6). The number of reads 
mapped to each gene were counted using featureCounts(7) and gene expression level was calculated 
as fragments per kilobase of transcript per million mapped reads (FPKM). GATK best practices was 
performed for variant calling on RNAseq(8). Data was submitted to the European Genome-phenome 
Archive (Accession-number EGAS00001001858). 
 
Immunofluorescence 
MUTZ-5 cells were fixated with 4% paraformaldehyde (PFA; Cat.#30525-89-4/158127; Sigma-Aldrich), 
permeabilized with methanol (Cat.#67-56-1; Sigma-Aldrich) at -20 °C and then stained with primary 
antibodies against either pan-RAS or bRAF. Secondary antibodies, labeled with either Alexa-488 
(green) or Alexa-594 (red), specific to the respective primary antibody species were used to visualize 
the spatial organization of RAS (mostly at plasma membrane) and RAF (mostly in cytoplasma) proteins 
in a LSM800 inverted confocal microscope with Airyscan, 63×/NA1.20W objective  (Carl Zeiss, 
Oberkochen, DE) at room temperature. Cell nuclei were stained with DAPI. Images were captured 




Quantitative PCR  
Quantitative PCR was performed using a StepOnePlus Real-Time PCR system (Applied Biosystems, 
Foster City, USA) with Power SYBR Green PCR master mix (Applied Biosystems) according to the 
standard manufacturer’s protocol. The expression of human CRLF2 or human JAK2 was standardized 







(Expanded results description) Higher levels of RAS protein and mRNA correlate with poor outcome 
in DS-ALL and non-DS childhood ALL 
The entire analysis shown so far was based on differences in activity of proteins targets. We also 
wanted to address protein expression levels in DS-ALL SR and HR groups. Based on individual protein 
expression levels (Supplementary-Fig.S7A), we found that overall levels of both RAS and rpS6 
positively correlated with HR, but levels of CRLF2, STAT5, JAK2, MEK1/2, or ERK1/2 did not. In order 
to examine similar correlations in non-DS ALL, the material availability only permitted us to look for 
differences in mRNA transcript levels of the same genes within the whole transcriptome RNA-seq data 
of the MS2003/2010 cohort (N=346 non-DS ALL cases; median follow-up via reverse Kaplan-Meier = 
7.64 years)(4, 5). CRLF2 mRNA expression (Supplementary-Fig.S7B) and Cox regression hazard ratio 
(Supplementary-Fig.S8A) were significantly increased in the poor first event samples (n=47). We 
focused all further analysis on non-DS B-ALL samples with high-risk genetics: Moderate or high CRLF2 
expression (log2(FPKM+1)>0.7) and excluded ALL-subtypes that are considered to confer favorable 
outcomes (ETV6-RUNX1, Hyperdiploid, TCF3-PBX1, DUX4 and ZNF384). Within the resulting HR sub-
cohort (n=91; median follow-up = 6.95 years) KRAS mRNA-expression was independently predictive 
of outcome (P=.030) when included in a multivariate analysis using Cox proportional hazards 
regression model together with Ph-like status, RAS mutation status, sex, and NCI risk (Supplementary-
Fig.S8B). Of all analyzed genes, exclusively KRAS and JAK2 mRNA expression correlated with poor 
outcome (Supplementary-Fig.S7B). However, only high KRAS mRNA-levels were also significant in 
Kaplan–Meier survival estimator (Supplementary-Fig.S8B). 
The combined data suggest that a large scale analysis on a non-DS ALL cohort is warranted for protein 
activation patterns of RAS, MEK1/2, and other pathway components activation readouts as this could 
potentially significantly inform the patient sub-stratification for outcome. This provides just a hint of 
a trend compatible with conclusions reached for the general role of RAS (irrespective of its mutational 
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status) as a biomarker in childhood ALL, but emphasizes the need to examine the protein-activation 
and inducibility parameters on a much larger cohort of non-DS ALL patients for a more accurate risk-





Case example: RAS activation explains the clonal evolution from presentation to relapse 
DS-ALL patient DS09 highlights the need for an even deeper understanding of the driving mechanisms, 
and the need to block wtRAS activation as part of the combinatorial treatment design. Exome 
sequencing found at presentation a JAK2-mutation (and no RAS-mutation). These DS09 blast cells 
were highly TSLP-inducible for RAS activity, which could be blocked very efficiently using RAS-inhibitor 
Salisarib, but not using JAK or PI3K inhibitors in vitro. Concordantly in the experiment in Fig.8C, only 
RAS-inhibition using Rigosertib significantly reduced viable cell numbers in the DS09-sample. The same 
patient relapsed two years after standard chemotherapy regimen, and the relapse sample contained 
no JAK2 mutations anymore, but the main blast had gained an NRAS mutation (sequenced as sample 
4-1036101-T2(3)). Interestingly, this relapse sample with constitutively activated NRAS shows no rpS6 
activity any longer (with or without TSLP-induction) and TSLP could only induce moderate levels of 
STAT5 activity compared to the presentation sample (Supplementary-Fig.S5A). 
 
(Expanded) RAS inhibition strategies 
The importance of identifying RAS activity for the patient outcome relies on the availability of 
effective RAS-treatments. RAS has been commonly deemed to be ‘undruggable’, a term describing 
the lack of RAS inhibitors that perform well pharmacologically. The RAS inhibitor Salirasib, a Farnesyl 
Thiosalicylic Acid (FTS) acts non-direct, as a mimetic of RAS for binding to RAS-escort proteins which 
selectively disrupts the association of RAS to the plasma membrane. It showed no effect in clinical 
trials on solid cancers trials(9) and requires relatively high dosage. We chose this RAS inhibitor for 
being able to use a single inhibitor that can block RAS activity of all the main RAS isoforms and most 
importantly can also block wtRas activity independent of RAS mutations. A new generation of RAS 
inhibitors are on the horizon(10) such as mutant-specific inhibitors of KRAS(G12C)(11). However, 
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based on our data, the focus should not lie on targeting mutant-RAS alone but also the inhibition of 
overstimulated activity in absence of RAS mutations. 
The RAS inhibitor Salirasib used in our study disrupts the spatiotemporal localization of active RAS 
but requires relatively high concentrations, thus rendering it ineffective in Phase II clinical trials(12).  
Newer RAS-inhibitors like the RAS-mimetic Rigosertib, which blocks the RBD in RAS-effectors, as 
seen for bRAF and p110αPI3K in our PLA analysis on MUTZ-5 cells, allowing the block of both wt and 
mutant RAS-activity. Rigosertib was effective in reducing the viable cell count in our DS-ALL samples, 
irrespective of mutation status, and is currently being evaluated in a Phase III study for 
MDS/AML(13). 
Treatments involving the inhibition of activated RAS, independent of mutation status, that block the 
activation of multiple RAS-effector pathways, could help to cripple the cancer cells’ ability to adapt. 
 
(Expanded) Potential roles of chromosome 21 genes relevant to leukemogenesis 
Increased propensity for early hematopoietic (both myeloid and lymphoid) cell fate can be influenced 
by trisomy of RUNX1(14, 15), whereas ERG trisomy is linked to skewing of cell fate towards 
megakaryocytic lineage (the most frequent AML form in DS)(16). Increased HGMN1-dose through 
trisomy 21 directly enhanced the early B-lymphocyte precursors, and could play a role as one of the 
initiating events in ALL leukemogenesis(17), whereas CHAF1B trisomy may increase the risk of 
AML(18). One of the most dose sensitive chromosome 21 genes known for multiple pathway de-
regulations when copy number is increased, is DYRK1A. Increased DYRK1A-dose could promote both 
AML and ALL pathogenesis(19, 20). Interestingly, both DYRK1A, and another chromosome 21 gene 
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DS01 Presentation BM B-II 65.0 N/A ALL N.D. M N/A N 4-23-T1
DS02 Presentation BM B-II 90.0 122800 ALL N.D. M HR Y
DS04 Presentation BM B-II 95.0 N/A ALL 47,XY,+21c M SR N 4-1030604-T1
DS05 Presentation BM B-II 95.0 N/A ALL N.D. M HR N
DS06 Presentation BM B-III 91.6 323000 ALL N.D. F HR N 4-37-T1
DS07 Presentation BM B-II 87.0 86400 ALL N.D. F HR Y
DS08 Presentation BM B-II 85.0 N/A ALL N.D. F SR N
DS09 Presentation BM B-II 70.0 18780 ALL 47,XY,+21c M SR Y 4-1036101-T1
DS10 Presentation BM B-II 62.0 35400 ALL 47,XY,+21c M HR Y 4-1036272-T1
DS11 Presentation BM B-III 91.0 N/A ALL 48,XY,+X,+21 M SR Y
DS16 Presentation BM B-II 90.0 2400 ALL N.D. M HR Y 4-44-T1
DS17 Presentation BM B-II 90.0 44600 ALL 47,XY,+21c[1 M HR Y 4-03-T1
DS18 Presentation BM B-II 86.0 23530 ALL N.D. M SR N 4-02-T1
DS20 Presentation BM B-II 80.0 11500 ALL 47,XX,t(8;14) F SR N 4-29-T1 also Remission sample tested
DS22 Presentation BM B-II 97.0 N/A ALL N.D. F NA Y
DS23 Presentation BM B-II 88.0 27400 ALL 47,XX,+21c F SR N 4-1044929-T1
DS26 Presentation BM B-II 88.0 N/A ALL 47,XX,+21c[1 F N/A N
DS27 Presentation N/A N/A N/A N/A ALL N/A M N/A N also Remission sample tested
DS29 Presentation BM B-II 87.0 55000 ALL 47,XY,+21c[1 M HR Y
DS30 Presentation PB B-II 82.0 206000 ALL N.D. F HR N
DS09R Relapse BM B-II 47.0 12200 ALL 47,XY,+21c M 4-1036101-T2
DS12R Relapse BM B-II 79.0 17000 ALL N.D. M
DS16R Relapse BM B-II 90.0 N/A ALL N.D. M 4-44-T2
DS19R Relapse BM B-II 88.0 221400 ALL N.D. M
DS22R Relapse BM B-III 87.0 46000 ALL N.D. F 4-29-T2
DS28R Relapse BM B-II 83.0 98400 ALL N.D. M
DS29R Relapse BM B-II 83.0 39800 ALL N.D. M
DS24m Remission BM N/A N/A N/A N/A N.D. M Y







subclassification Blasts % WBC Diagnosis Karyotype Gender NCI
Poor outcome 
(death or relapse)
NDS03 Presentation N/A N/A N/A N/A ALL N/A F N/A N
NDS04 Presentation BM B-II 93 97800 ALL N.D. M HR N
NDS05 Presentation BM B-II 82.8 56000 ALL 46,XX F HR Y
NDS06 Presentation BM B-II 89 80000 ALL 46,XX F HR N
NDS01R Relapse BM B-II 44.1 NA ALL N.D. F
NDS02R Relapse BM B-II 97 NA ALL N.D. M
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Supplementary-Tab.S1) Clinical and biological characteristics of the leukemia samples used in this study and 




of Bonferroni-corrected P -
values









 Comparison: Bonferroni p-
value after one-
way ANOVA:
Comparison: p-value: Holm-Bonferroni 
corrected p value:





— vs. hJAK2R683G >0.99999 JAK2 activity uninduced vs. TSLP 0.00043 0.00171 Uninduced (+DMSO) vs. TSLP (+DMSO) 0.01572 DMSO uninduced vs. DMSO TSLP >0.99999 RAS : p-PTPN11 0.001306 0.002612 Pan-Ras basal activity SR vs HR 0.01315 0.03165 Pan-Ras activity
— vs. hCRLF2 >0.99999 MEK1/2 activity uninduced vs. TSLP 0.00065 0.00195 Uninduced (+DMSO) vs. TSLP + Ras inh. >0.99999 DMSO uninduced vs. Ras inh. uninduced <0.00001 NC (rpS6 : p-bRAF) (uninduced vs TSLP) 0.956956 >0.999999 JAK2 basal activity SR vs HR 0.00053 0.00265 pan-Ras inh. vs. PI3K/mTOR dual inh. 0.023
— vs. hJAK2R683G + hCRLF2 0.00160 Pan-Ras activity uninduced vs. TSLP 0.00308 0.00616 Uninduced (+DMSO) vs. TSLP + JAK inh. 0.20936 DMSO uninduced vs. Ras inh. TSLP <0.00001 STAT5 basal activity SR vs HR 0.55617 0.55617 pan-Ras inh. vs. JAK inh. 0.023
hJAK2R683G vs. hCRLF2 >0.99999 PTPN11 activity uninduced vs. TSLP 0.01846 0.01846 Uninduced (+DMSO) vs. PLA negative control 0.04445 DMSO uninduced vs. PI3K inh. uninduced <0.00001 MEK basal activity SR vs HR 0.00495 0.01980 PI3K/mTOR dual inh. vs. JAK inh. 0.800
hJAK2R683G vs. hJAK2R683G + 
hCRLF2
0.00364 TSLP (+DMSO) vs. TSLP + Ras inh. 0.02177 DMSO uninduced vs. PI3K inh. TSLP <0.00001 ERK basal activity SR vs HR 0.00035 0.00209
hCRLF2 vs. hJAK2R683G + 
hCRLF2
0.00347 Fig.2D) TSLP (+DMSO) vs. TSLP + JAK inh. 0.00214 DMSO uninduced vs. JAK inh. uninduced >0.99999 Fig.7C S6 basal activity SR vs HR 0.01055 0.03165 JAK2 activity
Comparison: p-value: Holm-Bonferroni 
corrected p value:
TSLP (+DMSO) vs. PLA negative control 0.00102 DMSO uninduced vs. JAK inh. TSLP 0.33322 Comparison: Bonferroni p-
value after one-
 
pan-Ras inh. vs. PI3K/mTOR dual inh. 0.944
KRas activity uninduced vs. TSLP 0.00216 0.00648 TSLP + Ras inh. vs. TSLP + JAK inh. 0.13163 DMSO TSLP vs. Ras inh. uninduced <0.00001 DMSO vs. DMSO + TSLP 0.00748 Pan-Ras TSLP-induced activity SR vs 
HR
0.00383 0.00766 pan-Ras inh. vs. JAK inh. 0.944
NRas activity uninduced vs. TSLP 0.01905 0.03810 TSLP + Ras inh. vs. PLA negative control 0.03079 DMSO TSLP vs. Ras inh. TSLP <0.00001 DMSO vs. PTPN11 inh. + TSLP 0.01592 JAK2 TSLP-induced activity SR vs HR 0.00027 0.00161 PI3K/mTOR dual inh. vs. JAK inh. 0.944
HRas activity uninduced vs. TSLP 0.06632 0.06632 TSLP + JAK inh. vs. PLA negative control >0.99999 DMSO TSLP vs. PI3K inh. uninduced <0.00001 DMSO + TSLP vs. PTPN11 inh. + TSLP 0.00027 STAT5 TSLP-induced activity SR vs HR 0.00241 0.00722
DMSO TSLP vs. PI3K inh. TSLP <0.00001 MEK TSLP-induced activity SR vs HR 0.01622 0.01622 STAT5 activity
Fig.2E) Fig.8C) DMSO TSLP vs. JAK inh. uninduced >0.99999 ERK TSLP-induced activity SR vs HR 0.00163 0.00653 pan-Ras inh. vs. PI3K/mTOR dual inh. 0.606
Comparison: p-value: Holm-Bonferroni 
corrected p value:
Comparison (each mean compared to 




DMSO TSLP vs. JAK inh. TSLP 0.00589 S6 TSLP-induced activity SR vs HR 0.00032 0.00162 pan-Ras inh. vs. JAK inh. 0.002
AKT2 (℗-Ser474) unind. vs. TSLP 0.01657 0.05404 DS17 Ras inh. uninduced vs. Ras inh. TSLP >0.99999 PI3K/mTOR dual inh. vs. JAK inh. 0.002
CDKN1A (℗-Thr145) unind. vs. TSLP 0.00002 0.00015
DMSO vs. RAS comp. inh. 0.32889
Ras inh. uninduced vs. PI3K inh. uninduced 0.00111
cRAF (℗-Ser296) unind. vs. TSLP 0.01546 0.05404 DMSO vs. PI3K/mTOR inh. 0.91477 Ras inh. uninduced vs. PI3K inh. TSLP >0.99999 MEK1/2 activity
ELK1 (℗-Thr417) unind. vs. TSLP 0.00016 0.00097
DMSO vs. JAK inh. 0.51257
Ras inh. uninduced vs. JAK inh. uninduced <0.00001 pan-Ras inh. vs. PI3K/mTOR dual inh. 0.544
GAB2 (℗-Ser159) unind. vs. TSLP 0.01351 0.05404 DMSO vs. RAS comp. inh. + JAK inh. 0.04654 Ras inh. uninduced vs. JAK inh. TSLP 0.00006 pan-Ras inh. vs. JAK inh. 0.228
MYC (℗-Ser62) unind. vs. TSLP 0.01025 0.05124 DS16 Ras inh. TSLP vs. PI3K inh. uninduced <0.00001 PI3K/mTOR dual inh. vs. JAK inh. 0.544
PTPN6 (℗-Tyr536) unind. vs. TSLP 0.01570 0.05404 DMSO vs. RAS comp. inh. 0.00027 Ras inh. TSLP vs. PI3K inh. TSLP 0.31820
DMSO vs. PI3K/mTOR inh. <0.0001 Ras inh. TSLP vs. JAK inh. uninduced <0.00001 ERK1/2 activity
DMSO vs. JAK inh. 0.72408 Ras inh. TSLP vs. JAK inh. TSLP 0.02665 pan-Ras inh. vs. PI3K/mTOR dual inh. 0.824
DMSO vs. RAS comp. inh. + JAK inh. <0.0001 PI3K inh. uninduced vs. PI3K inh. TSLP 0.00944 pan-Ras inh. vs. JAK inh. 0.668
DS20 PI3K inh. uninduced vs. JAK inh. uninduced <0.00001 PI3K/mTOR dual inh. vs. JAK inh. 0.824
DMSO vs. RAS comp. inh. 0.00615 PI3K inh. uninduced vs. JAK inh. TSLP <0.00001
DMSO vs. PI3K/mTOR inh. 0.00588 PI3K inh. TSLP vs. JAK inh. uninduced <0.00001 rpS6 activity
DMSO vs. JAK inh. 0.69698 PI3K inh. TSLP vs. JAK inh. TSLP <0.00001 pan-Ras inh. vs. PI3K/mTOR dual inh. 0.066
DMSO vs. RAS comp. inh. + JAK inh. 0.00643 JAK inh. uninduced vs. JAK inh. TSLP 0.11829 pan-Ras inh. vs. JAK inh. 0.066
DS27 PI3K/mTOR dual inh. vs. JAK inh. 0.808
DMSO vs. RAS comp. inh. 0.00036
Supplementary-Fig.S1C) Supplementary-Fig.S2C,D,E) DMSO vs. PI3K/mTOR inh. 0.00143 Supplementary-Fig.S7A) Comparison: p-value: Holm-Bonferroni 
  Comparison: Bonferroni p-
value after one-
 
Comparison: p-value: Holm-Bonferroni 
corrected p value: DMSO vs. JAK inh. 0.1684
Comparison: p-value: Holm-Bonferroni 
corrected p value:
STAT5 phosph. (JAK inh. vs. vehicle control) 0.00000 0.00001
JAK2 mRNA levels: GRB2 : phospho-PTPN11 
(uninducedvsTSLP)
4.1E-06 0.000434405
DMSO vs. RAS comp. inh. + JAK inh. 0.00014
Pan-Ras protein expression SR vs. HR 0.00427 0.02564 Pan-Ras-GTP level (Ras inh. vs. vehicle control) 0.00004 0.00061
— vs. hJAK2R683G 0.00415 pan-RAS : bRAF (TSLPvsRigo) 8.2E-05 0.006362897 DS09 JAK2 protein expression SR vs. HR 0.07137 0.28547 rpS6 phosph. (PI3K inh. vs. vehicle control) 0.00062 0.00988
— vs. hCRLF2 >0.99999 pan-RAS : p110aPI3K (TSLPvsRigo) 0.00016 0.0118114 DMSO vs. RAS comp. inh. 0.02829 STAT5 protein expression SR vs. HR 0.14639 0.43916 ERK1/2 phosph. (JAK inh. vs. vehicle control) 0.00213 0.03193
— vs. hJAK2R683G + hCRLF2 0.01031 pan-RAS : phospho-PTPN11 
(TSLPvsRigo)
0.10487 0.97912792
DMSO vs. PI3K/mTOR inh. 0.85979
MEK1/2 protein expression SR vs. HR 0.40022 0.80045 rpS6 phosph. (JAK inh. vs. vehicle control) 0.00231 0.03231
hJAK2R683G vs. hCRLF2 0.00413 pan-RAS : phospho-PTPN11 
(uninducedvsTSLP)
1.7E-07 2.19501E-05
DMSO vs. JAK inh. 0.85979
ERK1/2 protein expression SR vs. HR 0.04039 0.20196 rpS6 phosph. (Ras inh. vs. vehicle control) 0.00320 0.04154
hJAK2R683G vs. hJAK2R683G + 
hCRLF2
0.69131 pan-RAS : PTPN11 (TSLPvsRuxo) 7E-06 0.000709391
DMSO vs. RAS comp. inh. + JAK inh. 0.15412
rpS6 protein expression SR vs. HR 0.00034 0.00237 MEK1/2 phosph. (JAK inh. vs. vehicle control) 0.00500 0.06004
hCRLF2 vs. hJAK2R683G + 
hCRLF2
0.01023 pan-RAS : SOS1 (uninducedvsTSLP) 0.00029 0.019530583 DS23 CRLF2 protein expression SR vs. HR 0.49585 0.80045 MEK1/2 phosph. (PI3K inh. vs. vehicle control) 0.00737 0.08112
rpS6 : phospho-bRAF (TSLPvsRigo) 3.6E-06 0.000387867 DMSO vs. RAS comp. inh. 0.00083 Pan-Ras-GTP level (JAK inh. vs. vehicle control) 0.01001 0.10007
Supplementary-Fig.S1D) rpS6 : phospho-bRAF (TSLPvsRuxo) 0.0004 0.025484468 DMSO vs. PI3K/mTOR inh. 0.1601 Supplementary-Fig.S7B) JAK2 phosph. (Ras inh. vs. vehicle control) 0.03552 0.31971
CRLF2 mRNA levels: Bonferroni p-
value after one-
way ANOVA:
rpS6 : phospho-bRAF 
(uninducedvsTSLP)
0.00148 0.070801112
DMSO vs. JAK inh. 0.12471
Comparison: p-value: Holm-Bonferroni 
corrected p value:
JAK2 phosph. (PI3K inh. vs. vehicle control) 0.05956 0.47652
— vs. hJAK2R683G >0.99999 rpS6 : phospho-rpS6 (TSLPvsRigo) 2E-05 0.001828029 KRAS mRNA good vs. poor outcome 0.02670 0.18693 JAK2 phosph. (JAK inh. vs. vehicle control) 0.06092 0.47652
— vs. hCRLF2 0.02509 rpS6 : phospho-rpS6 (TSLPvsRuxo) 9.9E-08 1.30439E-05 JAK2 mRNA good vs. poor outcome 0.03945 0.23670 ERK1/2 phosph. (PI3K inh. vs. vehicle control) 0.06835 0.47652
— vs. hJAK2R683G + hCRLF2 0.00020 rpS6 : phospho-rpS6 
(uninducedvsTSLP)
3.4E-07 4.28713E-05 NRAS/KRAS mRNA good vs. poor outcome 0.04616 0.23670 Pan-Ras-GTP level (PI3K inh. vs. vehicle control) 0.28436 >0.99999
hJAK2R683G vs. hCRLF2 0.02514 SOS1 : GRB2 (uninducedvsTSLP) 0.00023 0.016345942 STAT5B mRNA good vs. poor outcome 0.10881 0.43525 MEK1/2 phosph. (Ras inh. vs. vehicle control) 0.46249 >0.99999
hJAK2R683G vs. hJAK2R683G + 
hCRLF2
0.00020 RPS6 mRNA good vs. poor outcome 0.81850 >0.99999 STAT5 phosph. (Ras inh. vs. vehicle control) 0.56159 >0.99999
hCRLF2 vs. hJAK2R683G + 
hCRLF2
0.00077 MEK1/2 mRNA good vs. poor outcome 0.87458 >0.99999 ERK1/2 phosph. (Ras inh. vs. vehicle control) 0.63041 >0.99999





Comparison: p-value: Holm-Bonferroni 
corrected p value:
Day4: STAT5 activity uninduced vs. TSLP 0.00006 0.00039
— vs. hJAK2R683G >0.99999 JAK2 activity uninduced vs. TSLP 0.00043 0.00256
— vs. hCRLF2 0.98323 MEK activity uninduced vs. TSLP 0.00065 0.00325
— vs. hJAK2R683G + hCRLF2 0.00016 rpS6 activity uninduced vs. TSLP 0.00067 0.00325
hJAK2R683G vs. hCRLF2 0.98323 Pan-Ras activity uninduced vs. TSLP 0.00308 0.01053
hJAK2R683G vs. hJAK2R683G + 
hCRLF2
0.00016 PTPN11 activity uninduced vs. TSLP 0.01846 0.03692
hCRLF2 vs. hJAK2R683G + 
hCRLF2
0.00022 ERK activity uninduced vs. TSLP 0.02192 0.03692
15 
 
Supplementary-Tab.S2) List of Bonferroni-adjusted or Holm-Bonferroni-corrected P-values from all statistical 
tests engaging in multiple comparisons in this article. Original P-values before Holm-Bonferroni-correction are 
also listed; the P-values appearing in figures and supplementary figures are highlighted red. See Materials and 
Methods for more details about the statistical methods used. 
 
  


























Rev KRas amplicon 
1
GCACAGAGAGTGA










TACT Fwd KRas 
amplicon 2
CCACCAGCAATGCA











Rev KRas amplicon 
2
CCAAAGCCAAAAGC










ACACGGT Fwd KRas Seq3
GGTGTAGTGGAAAC












CTGTA Rev KRas Seq4r
GCCACTGTTTATCCA





















Rev KRas amplicon 
3A
GGGATAAGAAAGT













Supplementary-Tab.S3) List of oligonucleotides used to establish the mutation status of key genes involved in 
the analyzed pathways in the DS-ALL patients. Forward and reverse strand oligonucleotides were used to 
amplify genomic regions of interests (named Amp) in PCR and all primers were then used in Sanger sequencing 
on produced PCR amplicons. DNA of previously(3) whole-exome-sequenced samples was used as control for 






Supplementary-Fig.S1) IL-3 induces wtRAS activity and cell growth in murine pro B cells, but can be substituted 
by stable overexpression of constitutively active JAK2 and CRLF2. (A) Cell count of Ba/F3 cells (untransfected) 
over time. Cells were either cultured with 10 ng/mL IL-3 or without. 
(B) Ba/F3 cells were cultured in 10 ng/mL IL-3. 17 hrs before lysis, the culture medium was changed to medium 
containing either 10 ng/mL IL-3 or no IL-3. A RAS-pull-down assay was performed. Lysates of pull-down and input 
were loaded on separate SDS-PAGE gels followed by Western blotting. Before Western blotting, the top part of 
the gel loaded with the RAS-GTP pull-down samples was stained with Coomassie dye to visualize the GST-RBD 
to ensure pull-down samples were loaded equally. To assess the total protein and phosphorylated protein 
amounts on the same PVDF-membrane, membranes were stripped and reprobed with new antibodies. 
(C&D) Ba/F3 cells were stably transfected with hJAK2R683G, hCRLF2, or both constructs together. Quantification 
of qPCR results for human JAK2 mRNA expression (A) and human CRLF2 mRNA expression (B) for the stably 
transfected Ba/F3 cell lines. All gene expression levels were normalized to murine GAPDH expression. Error bars 
are SD and P-values were determined in one-way ANOVA and post-hoc Bonferroni multiple comparison. 
(E) Only the co-expression of human CRLF2 and a constitutively active JAK2R683G mutant construct enabled IL3-
independent growth of Ba/F3 cells. The expression of either hCRLF2 or hJAK2R683G alone is not sufficient to 
promote cell growth over the course of 4 days. Data shown reproduced the experiments already published by 
Yoda et al.(23) to ensure that the cellular model recreated in our laboratory behaves the same and as evidence 
of the correlation with the state of RAS activation in these cells (Fig.1). Error bars are SD and P-values from a 
one-way ANOVA with post-hoc Bonferroni multiple comparison for the last timepoint are symbolized as asterisks 
(***: P < 0.001) or ns (P > 0.05).  
(F) Ba/F3 cells were stably transduced (Lentiviral) with hCRLF2 alone, or followed by hJAK2R683G. This second set 
of Ba/F3 lines was generated independently of the transfected lines used in (A-E) and Fig.1. All cells were then 
starved from IL-3 and cells were lysed. Each cell lysate was split up for analysis in RAS-GTP pull-down assay and 





Supplementary-Fig.S2) CRLF2-signaling promotes direct protein-protein binding (quantitated by proximity 
ligation assays) of multiple components involved in RAS activation in the absence of RAS mutations in human 
Philadelphia-like (rearranged CRLF2, JAK2R683G) B-ALL cells.  (A) MUTZ-5 cells were PFA-fixed, permeabilized, 
and stained with DAPI. Primary antibodies against either pan-RAS or bRAF were used. Secondary antibodies 
specific to the respective primary antibody species labeled with either Alexa-488 (green) or Alexa-594 (red) were 
used to visualize the spatial organization of RAS (mostly plasma membrane) and RAF (mostly cytosolic) proteins 
in confocal microscopy. 
(B) Direct interaction between individual RAS proteins and the MAPK pathway protein bRAF was monitored via 
proximity ligation assay (PLA) in high-throughput microscopy. MUTZ-5 cells were induced with 20 ng/mL TSLP 
for 5 min. After blocking, antibodies against Pan-RAS and bRAF were used in conjunction with PLA rabbit and 
mouse probes to allow specific readout of RAS binding to bRAF proteins in single cells in a high-throughput 
manner. Fluorescent microscope image shows the PLA spots in DAPI-stained cells. Histograms show the 
distribution of the number of spots in all cells, negative assay controls only received one of the antibodies (PLA 
for two non-interacting antigens showed higher levels of spots than the assay control, but remained at 
background levels, not shown). A minimum of 600 cells were analyzed per sample. Non-linear Gaussian fitting 
curves were plotted. 
(C) Direct interaction between protein pairs involved in RAS activation (see cartoon below the graph) was 
monitored via PLA in high-throughput microscopy. MUTZ-5 cells were either not induced or induced with 20 
ng/mL TSLP for 10 min. Cells were fixed and permeabilized in a 96 well plate. After blocking, the indicated 
antibody pairs were used in conjunction with PLA rabbit and mouse probes to allow the amplification and 
staining of interaction-specific PLA spots. The negative control (NC) samples used antibodies for two cytosolic 
proteins (rpS6 and phosphorylated bRAF) that were not expected to directly interact. At least 1900 cells per 
condition were analyzed in a high-throughput manner. The bar graph shows the averages of 3 technical 
replicates. Error bars are SD and P-values shown are Student’s T-test after Bonferroni correction for sequential 
multiple comparison for all uninduced vs TSLP-induced pairs. 
(D) Direct interaction between protein pairs involved in RAS activation and the binding between RAS to RAS 
effectors was monitored via PLA in high-throughput microscopy. MUTZ-5 cells treated with 20 ng/mL TSLP were 
pre-treated with either DMSO or the RAS-GTP mimetic inhibitor Rigosertib (30 µM) for 1.5 hrs. Cells were fixed 
and permeabilized in a 96 well plate. After blocking, the indicated antibody pairs were used in conjunction with 
PLA rabbit and mouse probes to allow the amplification and staining of interaction-specific PLA spots. The 
negative control (NC) samples used antibodies for two cytosolic proteins (rpS6 and phosphorylated bRAF) that 
were not expected to directly interact. At least 700 cells per condition were analyzed in a high-throughput 
manner. The bar graph shows the averages of 3 technical replicates. Error bars are SD and P-values shown are 
Student’s T-test after Bonferroni correction for sequential multiple comparison for all DMSO vs Rigosertib pairs. 
(E) Direct interaction between protein pairs between RAS and PTPN11 was measured via PLA in high-throughput 
microscopy. MUTZ-5 cells treated with 20 ng/mL TSLP were pre-treated with either DMSO or 5 µM Ruxolitinib 
(JAK inh.) for 1.5 hrs. Cells were handled like in (D). The condition using antibodies for rpS6 and phosphorylated 
rpS6 verified that the JAK inhibitor was effective in this experiment. At least 20,000 cells per condition were 
analyzed in a high-throughput manner. The bar graph shows the averages of 3 technical replicates. Error bars 
are SD and P-values shown are Student’s T-test after Bonferroni correction for sequential multiple comparison 






Supplementary-Fig.S3) PLA detects rpS6-phoshporylation and interaction between RAS and p-PTPN11 pattern 
in Ba/F3 lines comparable to MUTZ-5 cells. 
(A) Activation of PI3K/mTOR downstream target rpS6 protein was monitored via PLA in high-throughput 
microscopy. Ba/F3 cell lines were IL-3 starved for 17 hrs. MUTZ-5 cells were either not induced or induced with 
20 ng/mL TSLP for 10 min. Cells were fixed and permeabilized in a 96 well plate. After blocking, antibodies against 
phosphorylated rpS6 and total rpS6 were used in conjunction with PLA rabbit and mouse probes to allow specific 
readout of rpS6 activation in single cells in a high-throughput manner. At least 10.000 cells were analyzed per 
sample. The graph summarizes the average PLA spot counts of 3 technical replicates. Error bars are SD and P-
values were determined in one-way ANOVA and post-hoc Bonferroni multiple comparison. 
(B) Ba/F3 cells were cultured in 10 ng/mL IL-3. 17 hrs before lysis, the culture medium was changed to medium 
containing either 10 ng/mL IL-3 or no IL-3. PLA protocol was performed like in (A). Direct interaction between 
RAS and phosphor-PTPN11 was measured via PLA in high-throughput microscopy. At least 2.500 cells were 
analyzed per sample. The graph summarizes the average PLA spot counts of 3 technical replicates. Error bars are 





Supplementary-Fig.S4) TSLP-induction actives STAT and PI3K/mTOR signaling in Ph-like B ALL cells. Titration 
of TSLP concentration in Ph-like B ALL cells. (A) Extension of Fig.2A. MUTZ-5 cells (Human Ph-like B-ALL cells 
bearing CRLF2-rearranged and spontaneous JAK2R683G mutation) were stimulated (or not) with 20 ng/mL 
human TSLP for 10 min before cell lysis. Lysates were loaded on an SDS-PAGE gel followed by Western blotting. 
To assess the total protein and phosphorylated protein amounts on the same PVDF-membrane, membranes 
were stripped and reprobed with new antibodies. The experiment was repeated 5 times independently and the 
graphs show the quantification for active STAT5 (phosphorylated STAT5), active ERK1/2 (phosphorylated 
ERK1/2) and active RPS6 (phosphorylated RPS6). Representative Western blots above the respective graph show 
the phosphorylated protein form and the total expression of each protein. 
(B) Effect of TSLP concentration titration. MUTZ-5 cells were incubated with the indicated amounts of TSLP (0 
ng/mL to 100 ng/mL) for 5 min and then the cells were lysed on ice. Each cell lysate was split up for analysis in 
RAS-GTP pull-down assay and for total protein signal. RAS-GTP pull-down and lysate samples were loaded on 
separate gels. An SDS-PAGE followed by Western blotting was performed. To assess the total protein and 
phosphorylated protein amounts on the same PVDF-membrane, membranes were stripped and reprobed with 
new antibodies. Left-hand side blots show the RAS-GTP pull-down while the right-hand side blots show whole 
cell lysates of the same samples. Antibody-targets are labeled on the right side of each image with black arrows 
indicating the respective protein band. 
(C) Whole, non-denatured lysate from uninduced or TSLP-induced (20 ng/mL, 10 min) MUTZ-5 cells was 
subjected to an antibody-microarray. Binding of Cy3-labeled, endogenous proteins was measured. 6 spots per 
antibody were averaged and normalized to the Cy3-control present on each microarray slide. To exclude changes 
that are due to epitope-obstruction from bound protein partners, the signal for phosphorylation-site-specific 
antibodies was normalized to the signal from each corresponding total antibody raised against the same 
(unphosphorylated) peptide sequence (for phosphorylation-sites marked with ^, no total peptide counterpart 
was contained on the microarray-slide). Changes in phosphorylation that originated completely from epitope-
availability were disregarded from the analysis altogether. BSA-spots (empty) were used to set and subtract 
background signal. For analysis, minimum signal threshold was set to 3% signal strength of the Cy3-normalization 
control. Heatmap shows the signal for all normalized phosphorylation-sites on the antibody microarray that 
passed the mentioned criteria (68/97). Black arrows indicate phosphorylation-sites that were also investigated 






Supplementary-Fig.S5) Western blots for all analyzed patient samples and the resulting quantified data for 
the sub-stratification of DS-ALL by PCA. (A) Primary samples of DS-ALL patients at presentation, relapse, or 
remission, as well as MUTZ-5 cells, were thawed and cells were gently recovered in 9 mL RPMI1640 (Cat.#11-
875-119; Life Technologies, Carlsbad, US) containing 20% characterized fetal bovine serum (FBS; 
Cat.#SH30071.03; GE Healthcare, Chicago, US), 20 U/mL Benzonase (Cat.#70746; EMD Millipore), 2 mM L-
Glutamine (Cat.#25030081 Life Technologies), and 100 U/mL Penicillin-Streptomycin (Cat.#15140122, Life 
Technologies). Cells were resuspended in 5 mL fresh medium without Benzonase. Cells were counted using the 
automated cell-counter NucleoCounter NC-250 (ChemoMetec, Allerod, DK) and viability was assessed via 
staining with Solution18 (Cat.#910-3018, ChemoMetec). Cells were seeded at 1.5×106 cells/mL density in IMDM-
complete (IMDM (Cat.#12440053; Life Technologies) with 10% FBS, 2 mM L-Glutamine, 100 U/mL Penicillin-
Streptomycin, 200 μg/mL apo-Transferrin (Cat.#11096-37-0; Santa Cruz Biotechnlogy), 0.1% 2-Mercaptoethanol 
(Cat.#21985023; Life Technologies), 1 μg/mL insulin (Cat.#11061-68-0; Sigma-Aldrich), 10 ng/mL IL-3 (Cat.#200-
03; Peprotech, Rocky Hill, US) and 10 ng/mL IL-7 (Cat.#200-07; Peprotech). After 24 hrs, surviving cells were 
reseeded at 1×106 viable cells/mL density in IMDM-complete. After 16 hrs the cells were reseeded at 1×106 
cells/mL density in 2 mL OptiMEM (Cat.#31985070; Life Technologies) with 5% FBS. After 3 hrs, cells were either 
left uninduced or induced with 20 ng/mL TSLP (Cat.#1398-TS; R&D Systems) for 10 min at 37 °C before lysis. 
Where indicated, patient cells were pre-treated during the 3 hrs incubation with DMSO (D), RAS-inhibitor (Ri), 
PI3K/mTOR inhibitor (Pi), or JAK inhibitor (Ji). For Western blot analysis, cells were lysed and loaded on an SDS-
PAGE gel. To assess the total protein and phosphorylated protein amounts on the same PVDF-membrane, 
membranes were stripped and reprobed with new antibodies. Antibody-targets are labeled on the right side of 
each image with black arrows indicating the respective protein band. As all lanes are shown for all gels in every 
specific staining, sample names that are crossed-out were either not part of the analysis, or showed too low 
loading in all expressed proteins to be used for any quantification. For blot imaging, each PVDF membrane piece 
was separately incubated with chemiluminescent HRP substrate solution (Cat.#WBKLS0500; EMD Millipore) for 
2 min and imaged via the auto-exposure function of the ChemiDoc MP imaging system (Bio-Rad Laboratories) 
within 100 sec exposure time to standardize the sensitive but otherwise semi-quantifiable enzymatic-based 
detection.  
(B) Quantification of Western blot signals in (A) for all DS-ALL samples at presentation as well as Non-DS (NDS) 
at presentation, DS complete remission (CR), and DS/NDS at relapse (boxed group at right end of each bar graph). 
For quantification, the raw images were analyzed in Fiji 1.52n (ImageJ, National Institutes of Health, US) using 
the subtract background process followed by measuring the signal peaks in the Gel Analyzer function. Microsoft 
Excel software was used to adjust all samples to either their loading control (β-actin) or the quantitative total 
protein fluorescent signal (AzureRed, Cat.#AC2124; Azure Biosystems, Dublin, US). All samples’ protein activity 
and total protein signals were normalized to the respective signal from the uninduced MUTZ-5 samples loaded 
as reference on each membrane. 81% of all analyzed samples showed sufficient signal in loading control and 
tested proteins to be appropriate for further normalization and analysis. The quantified phosphorylated protein 
signals were additionally adjusted to the respective quantified total protein loading. Brackets on top indicate 
the groups of the four RAS activity patterns presented in Fig.3C. White and black bar graphs show the basal and 
TSLP-induced activation levels, respectively, of STAT5, JAK2, MEK1/2, ERK1/2, and RPS6 while the dotted grey 
bar graphs show the respective total protein expression levels. Outcome of leukemia is symbolized as circle for 
good outcome and triangle for poor outcome; RAS pathway mutations (R), JAK2 mutations (J), or neither (wt) 






Supplementary-Fig.S6) PCA statistics and PCA cluster counts on primary DS-ALL and NDS-ALL blast cells. (A) 
Basal and induced activation levels for RAS, JAK2, STAT5, MEK, ERK, and RPS6, as well as CRLF2 protein 
expression, were fed into ViDaExpert v1.2 to calculate 3 main principal components (PC1-3) in a PCA analysis. 
Numbers in bold highlight the categories (field) with the greatest correlation within each PC. 
(B) Euclidean k-means clustering was performed in ViDaExpert v1.2 on the PCA analysis in (A) for k = 1 to 10 (6 
times each). In order to identify the minimal number of clusters needed for the grouping analysis, class-class 
deviation was averaged for each k (error bars are SD). Class-class deviation from sequential, increasing number 
of clusters stopped being statistically significant at k = 4 (doted line); * (P < .05), *** (P < .001), ns (not significant). 
(C) Number of samples within each of the four clusters identified in the k-means clustering of the PCA data 
represented in Fig.4A. Count of the different patient sample categories for each cluster. 
(D) Kaplan–Meier curves of DS-ALL patients. For this comparison, and cluster 2 (HR = high risk, see Fig.5) was 
split into two subclusters 2A and 2B (cluster 2B contains the DS-ALL presentation samples that grouped closest 
to MUTZ-5 in the PCA-based cluster analysis in Fig.5A; DS07, DS11, and DS22). Median survival for 
subcluster 2A was 5.49 and for 2B 2.72. 
(E) Unsupervised hierarchical clustering of all analyzed DS-ALL presentation samples for all 6 measured protein 
activities (basal and TSLP-induced) as well as CRLF2 protein expression. The clustering results were similar to the 
independent K-means clustering (indicated by the red/green colored bar underneath the sample IDs) of the PCA 
(Fig.4A), with 90% (18/20) of the samples clustered in the same groups by both methods. Presence of RAS 
pathway mutations (R), JAK2 mutations (J), or neither (wt) is indicated (no single patient in this cohort was found 






Supplementary-Fig.S7) Disease outcome-correlations with expression levels of components used in RAS-
pathway sub-stratification. Protein levels in DS-ALL (A) and mRNA levels in non-DS childhood ALL 
(MS2003/2010 cohorts) (B) 
(A) Average protein expressions of analyzed key pathway components are compared between the SR group (DS-
ALL patients at diagnosis in PCA cluster 1) and the HR group (DS-ALL patients at diagnosis in PCA cluster 2) 
identified in Fig.4. All error bars are SD. P-values shown are Student’s T-test after Bonferroni correction for 
sequential multiple comparison for all proteins analyzed. 
(B) Violin blots of the mRNA levels based on whole transcriptome RNAseq of the MS2003/2010 cohorts at 
diagnosis are shown for gene(s) equivalents to proteins analyzed in the DS-ALL cohort. The dashed line 
represents the median while the dotted lines above and below the median mark the respective quartiles. CRLF2 
was analyzed for outcome on the total non-DS ALL cohort (N = 346). Subsequently, all other shown mRNA 
expression levels (KRAS, KRAS&NRAS combined, STAT5B, JAK2, MEK1&2 combined, ERK1&2 combined, RPS6) 
were compared in B-ALL samples positive for CRLF2-mRNA expression (log2(1+FPKM) > 0.7) for the first event 
outcome. Poor first event for the MS2003/2010 cohort was defined as resistance, death or relapse; good first 
event means complete remission. Subtypes that are known to favor a good outcome were excluded from the 
analysis (ETV6-RUNX1, hyperdiploid, DUX4 and ZNF384). The resulting n=91 subcohort harbored 13 RAS 
mutations (4/19 poor outcome samples) and 6 JAK2 mutations (0/19 poor outcome patients) but never both 
together. For KRAS&NRAS combined, table details results of Cox proportional hazards regression. All error bars 
are SD. P-values shown were calculated using Student’s T-test. Bonferroni-P-values adjusted for sequential 






Supplementary-Fig.S8) Disease outcome-correlations and multivariate analysis for mRNA expression levels in 
non-DS childhood ALL (MS2003/2010 cohorts) of key components emanating from RAS-pathway sub-
stratification in primary samples at diagnosis (A) Kaplan–Meier estimates of event-free survival of all non-DS 
ALL patients (N=346) according to CRLF2-mRNA expression. Low, intermediate, and high curves for CRLF2-mRNA 
expression levels (overall P = .09) each represent one third of the cohort (bottom, mid, and top third, 
respectively). Table within the graph shows multivariate analysis using Cox proportional-hazards model for 
CRLF2-mRNA levels together with the prognostic factors Ph-like status, sex, and NCI risk groups. Patient numbers 
at risk for each year are given in the table below the survival curve.  
(B) Subsequently, all other mRNA expression levels (KRAS, JAK2, KRAS&NRAS combined, STAT5B, MEK1&2 
combined, ERK1&2 combined, RPS6) were compared in B-ALL samples positive for CRLF2-mRNA expression 
(log2(1+FPKM) > 0.7) for the first event outcome (Supplementary-Fig.S7B). Subtypes that are known to favor a 
good outcome were excluded from the analysis (ETV6-RUNX1, hyperdiploid, TCF3-PBX1, DUX4, and ZNF384). 
The resulting n=91 subcohort harbored 13 RAS mutations (4/19 poor outcome samples) and 6 JAK2 mutations 
(0/19 poor outcome patients), but never both together. Kaplan–Meier curves show estimates of event-free 
survival of the HR non-DS ALL subcohort (n=91) grouped by RAS (overall P = .08) or JAK2-mRNA (overall P = .2) 
expression levels. The tables within the graphs show multivariate analysis using Cox proportional-hazards model 
for either RAS-mRNA or JAK2-mRNA levels respectively, together with KRAS/NRAS or JAK2 activating mutations 






Supplementary-Fig.S9) Efficacy of the RAS inhibitor stratified by patient sample inducibility. Primary 
presentation samples of DS-ALL and non-DS ALL patients (characterized in Supplementary-Tab.S1) were cultured 
for 2 days (see Supplementary-Fig.S5A for details). Samples with sufficient cell count were treated with either 
0.5% DMSO (vehicle control) or 50 µM Salirasib (indirect pan-RAS inh.) for 3 hrs after which the cells were 
induced for 10 min with 20 ng/mL TSLP in serum-reduced medium. Cells were lysed and a RAS-GTP ELISA pull-
down assay was performed. The efficacy of the RAS inhibitor (expressed as RAS activity of inhibitor-treated 
divided by RAS activity of DMSO-treated) on ELISA-measured RAS activity in patient samples that were defined 
in Fig.3B as not TSLP-inducible for RAS is compared to those in which RAS activity was inducible by TSLP. If 
inhibitor treatment reduced the RAS activity by over 10% compared to vehicle-control (dashed line in plot), the 
sample was tallied as successful RAS blocking. A Fisher’s exact test was performed between the groups. 
 
